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Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine type of skin cancer 
associated with a poor prognosis. This carcinoma named after its presumed cell of origin, the 
Merkel cell, a mechanoreceptor cell located in the basal epidermal layer of the skin. However, 
this notion has challenged by suggesting epidermal stem cells, fibroblasts or pro/pre-B cells 
as possible cells of origin. Merkel cell polyomavirus (MCPyV) is the only known polyomavirus 
directly linked to human cancer. Approximately 80% of all MCCs are positive for viral DNA. 
UV exposure is the predominant etiological factor for virus-negative MCCs. Immune therapy 
is a promising treatment for MCC patients, but it has failed to arrest the cancer progression.  
Biomarkers discovery is an urgent, and high-throughput approaches were proposed. The 
high-dimensional data generation of genomic, transcriptomic, proteomic, and imaging data 
by high-throughput approaches are a new type of biomarkers discovery platform. These data 
analyses unveil the cell origin and phenotype. Characterization and phenotyping of cells and 
exosomes originating from polyomavirus-negative and polyomavirus-positive MCC cell lines 
and their content analyses uncovered differentially expressed proteins and exosomal 
miRNAs.  
Paper I, the result showed that MCPyV-negative and –positive MCC cell lines’ exosomes 
contain several proteins associated with tumor cell motility and metastasis. A list of vesicular 
proteins derived from the extracellular region identified for exosomes that could be 
recognition proteins by recipient cells.  
Paper II, the result showed that the exosomal miR-222-3p presence in all type of samples 
derived from MCC cell lines, healthy donors and MCC patients. The miR-222-3p selectively 
sorted, and its expressed level dropped down dependent on cancer and viral status in MCC 
patients in the circulation system. The target genes’ scanning indicates that the exosomal 
miR-222-3p play pleiotropic role dependent on recipient cells in health and disease.  
Paper III, the result showed that MCPyV-positive cell lines and their exosomes contain 
polyomavirus proteins. The cell phenotyping investigation revealed the MCPyV-negative MCC 
cell lines indicate to loss DNA, RNA and protein synthesis and their regulation system activity, 




modification sites. These may lead to transcription-associated mutation (TAM) and 
transcription-associated recombination (TAR), which gave a rise a high mutational burden of 
MCPyV-negative MCCs. The MCPyV-positive MCC cell lines showed upregulated expression 
of proteins involved in DNA and its regulation that indicates harnesses of polyomaviruses for 
DNA integration. In addition, there are upregulation of proteins on RNA, protein synthesis 
and their initiation and control, modification machinery such as the protein acylation. As for 
following, this process culminates in the viral proteins and genome synthesis. However, a 
fixed exosome-ER accession ability and a low activity on endocytosis and exocytosis sites 
indicate to reduce the chance of MCPyV spreading.  
The dissertation is the result of comparative and integrated analyses of polyomavirus-
negative and -positive MCC cell lines' and their exosomes' protein and miRNA profiling; 
discussion of the potential application of exosomes, proteins and microRNAs as biomarkers 
for the diagnosis, progression, and prognosis for MCCs. During this project generated data 
and storied in publicly available repositories for further screening and validation studies. This 
project proved the benefit of exploring MCC cell lines as a model system for MCCs, and 




1    Chapter: Introduction 
Cancer is a genetically and clinically diverse disease even within one type of cancer. The 
pathogenesis, aggressiveness, metastatic potential and response to treatment can be 
different among individual patients with the same kind of cancer that suggest the role of 
genetic factors in cancer pathogenesis [1]. Merkel cell carcinoma (MCC) is a rare, aggressive 
neuroendocrine form of skin cancer. The risk of developing Merkel cell carcinoma 
substantially increased among a large number of immunosuppressed patients, and precision 
medicine is needed [2]. Precision medicine is a core of biomarkers, which are highly specific 
in revealing information for diagnosis, prognosis, and therapy [3, 4]. Cancer biomarkers 
discovery approaches are molecular, cellular, and imaging methodologies focused on disease 
and drug mechanisms. Biomarkers play a role in cancer screening, early diagnosis, prognosis, 
prediction of treatment efficacy, and adverse reaction. Biomarkers have prognostic and 
predictive value [4]. 
 
 Cancer Biomarker  
Biomarkers are biological indicators of normal physiological and pathogenic processes, and 
pharmacological responses to a therapeutic intervention, which can be objectively measured 
and evaluated [5]. In cancer, biomarkers defined as biochemical substances elaborated by 
cancer cells due to the cause or effect of the malignant process [4, 6]. Ideally, cancer 
biomarkers should be detectable only in the presence of cancer. However, they can be 
endogenous products produced at a higher or less rate in cancer cells or products of newly 
switched on genes that remained inactive in normal cells [7]. Biomarkers include intracellular 
molecules or proteins in tissues or can be released into circulation and appear in body fluids 
such as blood, serum and plasma, urine, saliva, synovial, amniotic and vaginal fluids, semen 
and breast milk, and their presence in significant amount may indicate the presence of cancer 
[8]. Cancer biomarkers classified into prediction, detection, diagnostic, prognostic, and 
pharmacodynamic biomarkers [9]. Predictive biomarkers used in assessing the effect of 
administering specific agents, which will work best for an individual patient [10]. Diagnostic 




based on the distinguishing features between benign and malignant tumors [10]. 
Pharmacodynamic biomarkers are cancer markers utilized in selecting doses of 
chemotherapeutic agents in a given set of tumor-patient conditions [12]. However, the 
biomarker utility lies in its ability to provide an early indication of a disease or its progression. 
The biomarker should be easy to detect and measure across populations. 
 
 Merkel Cell Carcinoma  
MCC is a rare, aggressive neuroendocrine form of skin cancer with a rising incidence and a 
high mortality rate [13]. More than one-third of patients die of MCC, which making MCC twice 
as lethal as malignant melanoma [14]. Toker et al. initially described cancer in 1972, as a 
trabecular cancer of the dermis with a high risk of lymphoid metastasis [13]. The name was 
changed to MCC because tumor cells resemble Merkel cells, which are present in the basal 
layer of the epidermis around hair follicles, and share several neuroendocrine markers such 
as chromogranin A, synaptophysin and cytokeratin 20 [15]. However, this statement recently 
challenged by suggesting epidermal stem cells, fibroblasts or pro/pre-B cells as possible cells 
of origin with neuroendocrine differentiation because of the neoplastic transformation [15-




pathologist classification, the MCCs are members of the group tumor, which includes small 
cell carcinoma of lung, lymphomas, and neuroblastomas [18]. 
 
Figure 1. The MCC cells have a little cytoplasm and dense nuclear chromatin. The transmission electron 
microscopy (TEM) picture: Scale bar = 2 µm, x80 000 magnification. 
 
 Epidemiology 
The incidence rate of MCC is variable across different regions of the world. The Surveillance 
of Rare Cancers in Europe (RARECARE) database reported an incidence rate of 0.13 per 
100,000 between 1995 and 2002 [19]. In Norway, the incidence of MCC was stable over time, 
whereas the estimate continued to increase within the 2005-2008 period and achieved 0.3 
per 100,000 people a year in Sweden, in 2012 [14, 15, 20].  
The disease appears more often in men than in women, with men comprising 61 % of the 
cases. Though, in Finland and China have reported a slightly higher incidence in women [21, 




compromised patients are most susceptible to the MCC [2, 23]. The MCC is more frequent in 
patients with autoimmune disease, leukemia, lymphoma, HIV infected, and 
immunosuppressed due to organ transplantation or other causes [2, 23-27]. Chronic 
inflammatory disorders such as rheumatoid arthritis, Bowen’s disease, and chronic arsenic 
exposure have also associated with a higher incidence of MCC [28, 29]. The most common 
primary site is in the head and neck region with 45 % of the cases, and the onset of the disease 
often occurs at more than 50 years of age [30, 31]. In immunosuppressed individuals, the age 
of onset of MCC is lower than 50 years, and the mortality is higher than in immunocompetent 
patients [2, 13]. These findings indicate the crucial role of efficient immune surveillance in 
the control of tumor growth and progression. 
 
 Pathogenesis 
The pathogenesis of MCC not fully understood as the cell of origin, which mentioned in the 
previous section. Two causes can initiate MCC tumorigeneses, such as accumulation of UV-
induced mutations in the MCPyV-negative MCCs and the UV-induced initiation of MCPyV-
encoded primary transforming genes activity in Merkel cell polyomavirus (MCPyV)-positive 
tumors [32, 33].  
The DNA sequencing revealed the crucial differences between MCPyV-negative and –positive 
MCCs, which are the abundance of UV-induced mutations as C-to-T pyrimidine dimers in 
MCPyV-negative MCCs, which are also typically evidence in other skin cancers associated with 
sun exposure, such as melanoma, basal cell carcinoma, and cutaneous squamous cell 
carcinoma [32]. Also, the comparative molecular genetics of MCPyV-negative and –positive 
MCCs identified significant differences in mutational burden, that was 0.4 
mutations/mutational burden in MCPyV-positive tumors compared to 10 
mutations/mutational burden in MCPyV-negative MCCs [15]. Moreover, exome sequencing 




tumors compared to 12.5 variants in MCPyV-positive MCCs, with no mutations in the 
retinoblastoma tumor suppressor (RB1)  and p53 [34].  
MCPyV is the only known polyomavirus that directly linked to human cancer [35]. MCPyV 
DNA clonally integrated into 80 % of the MCC tumors, and constant expression of MCPyV 
oncogenes required for MCC tumors cell survival, suggesting that the virus could be a 
causative agent in MCC tumors initiation and progression [35]. The polyomavirus genome 
consists of early and late coding regions that play a role in infectivity. The polyomavirus 
infection characterized by the expression of early antigens the large T antigen (LT), small T 
antigen (ST), and the 57 kD T antigen followed by late capsid proteins, such as VP1, VP2, and 
VP3 [36]. In MCC, the virus integrates into the genome at a nonspecific binding site and 
expresses the LT and ST antigens of viral oncogenesis [37]. The truncated domain of LT may 
play a role in shifting from the virus replication and virion release to clonal integration and 
tumorigenesis [38]. LT targets the RB1 and alter cell cycle progression and contributing to 
unregulated cell proliferation [39]. The ST bind the tumor suppressor protein phosphatase 2A 
regulates the function of F-box/WD repeat-containing protein 7 (FBXW7) in MCCs [40]. 
Murine models suggest that ST may be responsible for initiation of tumorigenesis, while LT 
maintains it, but the interplay of LT and ST in this oncogenic cascade has not been fully 
explored [41]. As mentioned above, the integration into the host genome is not part of the 
polyomavirus’ normal life cycle gives rise the tendency that UV radiation may induce 
mutations in the viral genome that drive oncogenesis, while evasion of the immune response 
facilitates cellular proliferation [42].  
 
 Diagnosis 
The clinical features of MCCs are a rapidly growing, cutaneous or subcutaneous tumor that is 
located mostly on the sun-exposed area, particularly the head and neck, less frequently, the 




asymptomatic and multiple lesions arising at different body sites have been observed [15]. 
Ulceration is uncommon. 
In addition to clinical examination, a biopsy’s histopathological features and the 
immunological markers expression profile is sufficient for a definitive diagnosis. MCC cells 
express several of types I and II cytoskeletal keratins, such as cytokeratin 20 (CK20), CK8, 
CK18, and CK19 [45]. Also, MCC cells express neuroendocrine markers such as synaptophysin, 
chromogranin A, neural cell adhesion molecule 1 (CD56), neuron-specific enolase (NSE), 
calcitonin, neurofilament (NF), high molecular weight cytokeratin (CK-HMW), protein gene 
product 9.5/ubiquitin C-terminal hydrolase 1 (PGP9.5/UCHL-1), somatostatin, paired box 
protein Pax-5 (PAX5), DNA nucleotidylexotransferase (TdT) [45-47]. Positivity for oncoprotein 
huntingtin-interacting protein 1 (HIP1), cluster of differentiation 99 (CD99), mast/stem cell 
growth factor receptor Kit (CD117), epithelial cell adhesion molecule (EpCAM), neurogenic 
locus notch homologue protein 1 (NOTCH1) and tumor protein 63 (p63) has been observed 
[15, 48]. MCC is negative for thyroid transcription factor 1 (TTF1), transcriptional regulatory 
protein ASH1 (ASH1), vimentin, S100 calcium-binding protein B (S100B), and CK7 [15, 49]. 
The p63 linked associated with a worse prognosis, and variable numbers of tumor-infiltrating 
cytotoxic T lymphocytes in a subset of MCC cases related to a better prognosis for MCC 
patients [50, 51]. 
 
 Treatment Options 
To treat Merkel cell carcinoma using the following surgical procedures as the wide local 
excision and lymph node dissection [52].  The cancer specimen and a sentinel lymph node 
biopsy can be done during the surgery. After the cancer removal, some patients receive 
adjuvant therapy that is chemotherapy or radiation to kill any cancer cells that are left [52].  
External radiation therapy is a machine outside the body to send radiation toward cancer 
[52]. External radiation therapy is used to treat Merkel cell carcinoma, and to relieve 
symptoms and improve quality of life as palliative therapy. Nowadays included in the course 
of Merkel cell carcinoma immunotherapy [53]. The immunotherapy treatment uses the 




therapy: PD-1 inhibitor and CTLA-4 inhibitor [53, 54]. The PD-1 inhibitor is a protein on the 
surface of T cells that help keep the body's immune responses active. When PD-1 attaches to 
another protein called PDL-1 on a cancer cell, it stops the T cell from killing the cancer cell. 
PD-1 inhibitors attach to PDL-1 and allow the T cells to kill cancer cells [55]. Avelumab and 
pembrolizumab use to treat advanced Merkel cell carcinoma [55, 56]. Nivolumab studied to 
treat advanced Merkel cell carcinoma [56]. The CTLA-4 inhibitor is a protein on the surface of 
T cells that help keep the body’s immune responses in check [54]. When CTLA-4 attaches to 
another protein called B7 on a cancer cell that stops the T cell kill the cancer cell. CTLA-4 
inhibitors attach to CTLA-4 and allow the T cells to kill cancer cells [54]. Ipilimumab is a type 
of CTLA-4 inhibitor studied to treat advanced Merkel cell carcinoma [54]. 
 
 Exosomes as a Source of Biomarkers 
Exosomes are small (30-300 nm), circulating, membrane-bound vesicles, taken in via 
endocytosis from the outer cell membranes and released via exocytosis following membrane 
fusion of multivesicular bodies (MVBs) [57, 58].  Exosomes as a source of biomarkers have 
not entirely validated and explored yet. 
 
 Exosomes Sources 
Exosomes can be isolated from nearly every fluid in the body, but for optimal diagnostic or 
prognostic value, blood is a reasonable first choice [59]. Blood contacts every organ 
system.  Other biological fluids such as amniotic fluid, breast milk, saliva, tears, and urine 
content exosomes as well as in vitro in cell culture media [59].  
 
 Exosomes Characteristics 
Exosomes created when intraluminal vesicles (ILVs) formed by inward budding of the 




that fuse with the plasma membrane and release their content as exosomes in the 
extracellular compartment [60, 61]. 
Initially, exosomes were considered to be involved in garbage disposal [62]. However, more 
experiments have revealed that exosomes are essential mediators for intracellular 
communication and subject to specific sorting mechanisms under both physiological and 
pathophysiological conditions, like cancer [63]. Increasing evidence suggests that exosomes 
are important in tumor growth and progression, cancer metastasis, avoiding apoptosis, 
mediate virus transmission and providing drug resistance [64-67].  
 
 Exosomes Composition 
Exosomes formed to encapsulate a small sampling of the plasma membrane, which carries 
different types of molecules such as proteins, lipids, DNAs, RNAs, including mRNAs and 
microRNAs [68]. One of the more common exosomal cargos used in the diagnosis and 
prognosis of the disease is microRNAs (miRNAs) [68]. microRNAs are small non-coding RNAs, 
about 17-25 nucleotides in length. Their presence or absence used as a biomarker to directly 
predict disease risk, progression or remission [69].  Isolating miRNAs from exosomal fractions 
has been standardized and now its a commonly used method for enriching for disease-
specific miRNAs from across the body or within a specific organ system [69].  Moreover, it has 
shown that exosomes derived from virus-infected cells, including the human tumor viruses 
Hepatitis C-virus (HCV), Epstein- Barr virus (EBV) and Kaposi’s sarcoma-associated herpesvirus 
(KSHV), can contain both functional viral proteins and nucleic acids that can aid oncogenesis 
[70, 71]. It has also suggested that non-enveloped viruses deploy exosomes for infecting cells 
and immune system avoidance [71]. 
Decode disease states with exosome biomarkers, whether in a cell line or across a human 






2    Chapter: Objective 
 
The overall aim of this Ph.D. project was to investigate exosomes originated from MCPyV-
negative and -positive MCC cell lines as a potential prognostic and diagnostic biomarker. 
 
The specific objectives of Paper I are 
1) To explore the protein content of MCC cell lines’-derived exosomes;  
2) To perform the comparative analysis of exosomal protein expression originated 
from Merkel cell polyomavirus (MCPyV)-negative and MCPyV-positive MCC cell lines. 
  
The specific objectives of Paper II are 
1) To investigate the exosomal miRNAs from MCPyV-negative and –positive MCC cell 
lines’ cells by next-generation sequencing (NGS);  
2) To screen the significant exosomal miRNA findings in serum/plasma samples from 
healthy donors and patients. 
 
The specific objectives of Paper III are 
1) To investigate the MCC cell lines’ cells’ phenotype; 
2) To perform comparative and integrative analyses to evaluate the role of exosomes 




3    Chapter: Choice of Methods 
In this thesis were used experimental research methods, which described in detail in the 
individual studies. This part provides a broad overview of three methodologies such as 
proteomics, transcriptomics and high-dimensional data analyses for cancer-biomarkers 
discovery and methods' benefit and disadvantage. 
 
 Proteomics in Cancer Biomarkers Discovery 
The technical approaches at the system level give great potential to aid in the identification 
of the novel therapeutic target and disease biomarkers.  The proteome displays plasticity is 
owing to alternative splicing events, protein modifications, and the ability to merge into 
complexes and signaling networks [72]. Proteomics is the deciphering of how molecules 
interact as a system for our understanding of the functions of cellular systems in healthy and 
disease states. Post-translational modifications (PTMs) modulate protein activity, stability, 
localization, and capacity, which play essential roles in many critical cells signaling events 
both healthy and disease states [72-74]. Dysregulation of number of PTMs such as protein 
acetylation, glycosylation, hydroxylation, and phosphorylation implicated in a spectrum of 
human diseases including cancer [72-74]. Furthermore, genetic mutations give the rise 
different protein sequence variations, and alternative splicing are common causes of human 
diseases including cancer [75]. Discovery of potential biomarkers for MCC using Mass tandem 
spectrometry (MS) have chosen for the project. Protein identification by MS carried out in 




strategy allows the complete characterization of protein isoforms and post-translational 
modifications [76, 77].  
 
Figure 2. Procedures for MS-based protein identification and characterization. Proteins extracted from 
biological samples analyzed by bottom-up or top-down methods. The top-down approach fit for whole-protein 
analysis. The bottom-up strategy befits for analysis of enzymatically or chemically produced peptides. 
 
We used Q Exactive HF-X hybrid Quadrupole-Orbitrap Mass Spectrometer. This MS involves 
a gas-phase ionization of intact proteins and subsequent high-resolution mass measurement 
of intact protein ions followed by their direct fragmentation inside the MS, particularly high-
energy collision dissociation (HCD), without prior digestion [77, 78]. The proteins sequenced 
with higher activation energy and shorter activation time. HCD generates b- and y-type 
fragment ions, while the higher energy leads to a predominance of y-ions, b-ions can be 
fragmented to a-ions or smaller species [79]. This HCD ability provides more informative ion 




diagnostic ions specific to HCD could be recognized for PTMs identification. MS-based 
proteomics analysis detects PTMs that occurs on the amino acid side chains or the amine and 
carboxyl terminal of the protein [80, 81]. HCD works well for most stable modifications such 
as acetylation and methylation. HCD provides rich fragments ion spectra for 
phosphopeptides, and the optimized alternating acquisition method improves the 
identification coverage and accurate site localization for phosphoproteomics analysis [81]. 
HCD enables the identification of glycan structure and peptide backbone, allowing 
glycopeptide identification. HCD detects glycan oxonium ions from Orbitrap (MS2) [82]. 
Ubiquitination detection used alternative fragmentation or intelligent acquisition, which 
provides complementary information for peptide identification and modification site 
localization [83]. The protein S-nitrosylation is an extremely labile modification due to the 
nature of NO attachment to the specific protein cysteine suppressive peptide backbone 
fragmentation due to the neutral loss of NO group under the fragmentation mode [84]. SS-
containing peptides efficiently can be fragmented with HCD in a Q Exactive Orbitrap MS, 
preserving SS for subsequent identification [85]. However, the top-down approach is facing 
challenges associated with protein solubility, separation, the detection of large intact 
proteins, as well as the complexity of the human proteome.  
 
 Transcriptomics: Comparative Evaluation of Exosomal microRNA Profiling by 
Next-Generation Sequencing and qPCR-based Method in Biofluids 
MicroRNAs are a class of small RNAs that function as regulators involving in many biological 
processes [86]. The evaluation of miRNAs and their targets has aided by miRNA expression 
profiling studies including multiplex PCR, microarrays, and next-generation sequencing (NGS) 
tools [86-88]. In this project, the exosomal miRNA originated from MCPyV-negative and –




serum/plasma exosomal miRNAs from healthy donors and patients with MCC by the qPCR-
based method. 
There are pros with NGS [89, 90]: 
 NGS provides thousands of genes profile in a single experiment;  
 There are no background signal and cross-hybridization issues of microarrays; 
 By NGS enables the identification of isomiRs, microRNA variants that differ in 
sequence or length from the annotated species in miRBase; 
 NGS allows for the simultaneous confirmation of known miRNAs and discovery of new 
miRNAs;  
 Costs reduced while providing billions of nucleotide information within a single 
experiment.  
The procedure of generation of miRNA library for NGS is a prime part of the experiment 
(Figure 3) [90, 91]. The small RNA sequencing library generates by adapters ligated the miRNA 
in both ends, followed by reverse transcription (RT), template amplification by PCR and size 
selection of small RNA species. Several of these steps have shown to introduce biases and 
artifacts (Figure 3). Specific adapter-miRNA pairs or sequence compositions can be favored 
over others during ligation and PCR amplification, which resulting over- or 
underrepresentation of these miRNAs in the sequencing library [91]. The formation of 
adapter dimers or inefficient size-selection may lead to enrichment for miRNAs over other 




challenge for the discovery of biofluids-based miRNA biomarkers is a low amount of RNA 
input [90, 91]. 
 
Figure 3. Overview of the small RNA sequencing library preparation workflow. Many kits adapted a ligation-
based approach to attach 3’ and 5’ adapter to the miRNA. A unique barcode, unique molecular indices (UMI) 
connected at the RT stage. Illumina adapter and sequencing index for multiplexing added during the PCR 
amplification (https://www.biocat.com/ngs/exosomal-rna-sequencing).  
 
There is an overall good agreement between NGS and qPCR, but some differences between 
the platforms, highlighting the importance of validation exist (Table 1) [92]. NGS and qPCR-




and useful for low target numbers. The critical difference between NGS and qPCR-method is 
discovery power (89, 92). 
 
Table 1. The benefits and challenges between the NGS and qPCR methods. 
 NGS qPCR 
Benefits  Higher discovery power 
 Higher sample 
throughput 
 Familiar workflow 
 Equipment placed in 
most labs 
Challenges  Less cost-effective for 
low sequencing numbers 
of targets 
 Time-consuming for low 
sequencing numbers of 
targets 
 A limited set of variants 
 No discovery power 
 Low scalability 
 
 
 Biodata Platform and Analysis Tools 
Advances in high-throughput techniques including next-generation sequencing, RNA 
sequencing, and proteomics have generated an enormous volume of data [93–96]. The 
technological development reduces the amount of sample material, to collect raw data takes 
a short time and substantially decreased the costs. Hence, large-scale approaches are now 
available by many research laboratories. The complex high-throughput data interpretation 




Specific laboratories or groups and companies develop most of the software tools designed 
to perform the required examination for the group of data and professional [101]. 
In this project, for the comparative and integrated proteomic and sequencing data analyses 
performing used following different biodata platform and analysis tools: 
The ExoCarta is a database for molecular data, such as proteins, RNA, and lipids, identified in 
exosomes [102]. The ExoCarta cataloged only exosomal studies reported by the authors, and 
the challenge is no segregation of extracellular vesicles (EVs) classes [102].  
The Vesiclepedia is a repository with data from all types of EVs to understand molecular 
repertoire of a different kind of EVs and their biological functions [103]. Users can query or 
browse through proteins, lipids, and RNA molecules identified in EVs. The selected 
protein/miRNA of interest instructs to a gene page with information of external references 
to other primary databases, the experiment description of the study that identified the 
molecule, gene ontology-based annotations, protein-protein interactions, and a graphical 
display of network with relevance to molecules identified in EVs [103]. Gene ontology 
annotations of molecular functions, biological process, and subcellular localization retrieved 
from Entrez Gene [98]. The protein-protein interaction data obtained from HPRD, BioGRID, 
and Human Proteinpedia [104-107]. 
The FunRich is an open-access functional enrichment analysis tool for the omics data [108]. 
Using FunRich, users can perform functional enrichment analysis with minimal or no support 
from computational and database experts for more than 13,320 species. The database 
integrated from heterogeneous genomic and proteomic resources (>6.8 million annotations) 
[108]. The FunRich uniquely allows the users to update the background database for 13,320 
species from UniProt, Gene Ontology and Reactome in real time [98, 108-110]. In miRNA 
enrichment analysis, users can submit a list of miRNA and identify biological pathways. Also, 




expression values [108]. The quantitative data can also be utilized to generate customizable 
heat maps. The FunRich allows users to download data from Vesiclepedia [108].  
For the analysis and identification of miRNA-target interactions (MTIs), many web-based 
miRNA-related databases have established:  
The miRBase is one of many primary miRNA sequence repositories that facilitate searches for 
comprehensive miRNA nomenclature, sequence, and annotation data [111].  
The miRTarBase database aim is to provide a more comprehensive collection of 
experimentally supported MTIs in data content and the web-based function, to accelerate 
miRNA research [112].  
The TargetScan is a web server for miRNAs target prediction by searching the presence of 
sites that match the seed region of miRNA [98, 111, 113-119].  
Many databases integrated, such as: 
 miRBase and HMDD for miRNA and disease information;  
 The NCBI Entrez Gene and RefSeq for target gene information and 3’ untranslated 
region of target sequences;  
 The Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) for gene 
and miRNA expression profiling;  
 KEGG and DAVID for functional annotations of miRNA target genes.  
The PubMed integrated to provide article information [120]. 
The MaxQuant with the integrated Andromeda search engine is a quantitative proteomics 
software package, which designed for analyzing sizeable mass-spectrometric data sets, 
specifically a high-resolution MS data [121, 122]. Several labeling techniques and label-free 
quantification support the MaxQuant. MaxQuant is freely available. The download includes 
the search engine Andromeda integrated into MaxQuant and the viewer application for 
inspection of raw data, identification and quantification results [122]. For statistical analysis 
of MaxQuant output offers the Perseus framework [123]. 
The Perseus is a software platform for interpreting protein quantification, interaction and 
post-translational modification data [123]. The Perseus contains a broad scope of statistical 




analysis, cross-omics comparisons, and multiple-hypothesis testing. A machine learning 
system supports the classification and validation of a group of samples for diagnosis and 
prognosis and detects predictive protein signatures [123, 124].  
The Universal Protein Resource (UniProt) provides protein information [98]. The UniProt 
website provides ten main datasets and three main tools. The key UniProt datasets are the 
UniProt Knowledgebase (UniProtKB), the UniProt Reference Clusters (UniRef), the UniProt 
Archive (UniParc) and protein sets for completely sequenced genomes (Proteomes) [98, 125]. 
Supporting datasets include information about proteins that are present in UniProtKB protein 
entries like literature citations, taxonomy, subcellular locations, keywords, cross-referenced 
databases, and diseases [126]. The three tools that UniProt provides are the ‘Blast’ sequence 
search tool, the ‘align’ multiple sequence alignment tool and the ‘Retrieve/ ID Mapping’ tool, 
where users can upload lists of identifiers to download corresponding UniProt entries or map 
them to/ from external databases [125, 126]. 
The Proteome Discoverer is a software to process and report mass spectrometry data [127]. 
The raw data from mass spectrometry or spectral libraries compare the information from a 
selected FASTA database and identifies proteins from the mass spectra of digested fragments 
[127, 128]. The application does the following:  
 The peak-finding search engines, such as Sequest™ HT and Mascot to process all MS 
data types and generate a peak list and relative abundances. The peaks represent the 
fragments of peptides with a given mass and charge [127]; 
 Results from several database searching engines and multiple analysis combine, filter 
and annotate [127].  
The FASTA database utilities to add, delete, and find protein references and sequences [128]. 
The Gene Ontology (GO, www.geneontology.org) describes the function of gene products 
from all organism, specifically designed for supporting the computational representation of 
biological systems [98, 109, 129]. 
High-throughput techniques and big biological data analysis tools enable us to translate a 









4    Chapter: Summary of Main Results 
 Paper I. Secretomic Analysis of Extracellular Vesicles Originating from 
Polyomavirus-Negative and Polyomavirus-Positive Merkel Cell Carcinoma Cell Lines 
In Paper I, we studied the protein content of MCC cell line-derived exosomes by mass tandem 
mass spectrometry. Since approximately 80% of all MCC cases contain Merkel cell 
polyomavirus (MCPyV), the exosome of two MCPyV-negative and two MCPyV-positive MCC 
cell lines compared. We identified with high confidence 164 exosome-derived proteins 
common for all four cell lines that annotated in ExoCarta and Vesiclepedia databases. These 
include proteins implicated in motility, metastasis and tumor progression, such as integrins 
and tetraspanins, intracellular signaling molecules, chaperones, proteasomal proteins, and 
translation factors.  
 
 Paper II. Comparative Analysis of microRNA Expression Profiles of Exosomes 
Derived from Polyomavirus-Negative and –Positive Merkel Cell Lines by Next-
Generation Sequencing 
In Paper II, we sequenced exosomal miRNAs of MCC cell lines MCPyV-negative and –positive, 
and main findings validated on exosomes from serum/plasma healthy donors and MCC 
patients by the qPCR-based method. Our results showed that the exosomal miR-222-3p 
presence in all type of samples derived from MCC cell lines, healthy donors and MCC patients.  
There is a statistically significant difference between the miR-222-3p levels in the exosome 
samples from MCPyV-negative and -positive MCC cell lines. The level of miR-222-3p in 
exosomes from MCPyV-negative MCC cell lines than MCPyV-positive, which we assume as a 
tumor environment. Because of previously in miRNA studies in MCCs were not the miR-222-
3p mentioned, it indicates that the miR-222-3p sorted selectively in exosomes. Its expressed 
level dropped down dependent on cancer and viral status in MCC patients in the circulation 
system. The scanning of miR-222-3p target genes indicates that the exosomal miR-222-3p 
play pleiotropic role dependent on recipient cells in health and disease. Exosomes derived 




circulation system. They appear to transport especially sorted functional proper such as 
miRNAs as messengers to target and recipient cells.  
 
 Paper III. Comparative and Integrated Analyses of Polyomavirus-Negative and –
Positive Merkel Cell Carcinoma Cell Lines and their Exosomes Proteomic Profiles 
In Paper III, using experimental and computational approaches, we identified MCPyV 
proteins in MCPyV-positive MCC cell lines and their extracellular vesicles. The viral 
oncoproteins large and small T-antigens detected in the MCPyV-positive cells, and exosomes 
derived from these cells. Our results suggest that exosomal transmission of MCPyV 
oncoproteins to recipient cells in the tumor microenvironment contributes to tumorigenesis. 
Moreover, our proteomic data may identify unique biomarkers for MCPyV-negative and –
positive MCCs, reveal their origin and may allow the design of specific therapeutic strategies 






5    Chapter: General Discussion 
In the present thesis, proteomics and transcriptomics provide an invaluable source of 
biological structures and function at proteins and global exosomal miRNAs levels in MCPyV-
negative and –positive MCC cell lines and their exosomes. 
This thesis aimed to research of MCC cell lines and their exosomes potential prognostic and 
diagnostic biomarkers by high-throughput techniques and big data analyses tools. 
In this project done the first comparative proteomic study of exosomes originated from 
MCPyV-negative and –positive MCC cell lines (Paper I) and MCPyV-negative and –positive 
MCC cell lines to explore the phenotype of cells (Paper III). Proteomic profile revealed MCCs’ 
cellular and molecular mechanisms of carcinogenesis and metastasis (Paper III). Moreover, 
we did the first study that identified MCPyV proteins in MCPyV-positive MCC cell lines and 
their extracellular vesicles by mass tandem spectrometry (Paper III). Integrative analyses of 
MCPyV cell lines and their extracellular vesicles from the previous study (PXD004198, Paper 
I) revealed that exosomes carried MCPyV oncoproteins, which may transmit to target and 
recipient cells in the tumor microenvironment and circulation system (Paper III). 
Furthermore, this is the first study that investigated the exosomal global miRNAs expression 
from MCPyV-negative and –positive MCC cell lines (Paper II). In addition, the screening done 
in exosomal serum/plasma samples from healthy donors and MCC patients (Paper II). Also, 
the current project provides proteomic and transcriptomic studies, and sharing data through 
publicly available data repositories with all research community for the understanding of 
MCCs pathophysiology (Paper I, II, and III). Proteomic and transcriptomic data are a core of 
biomarkers, which are highly specific in revealing information for diagnosis, prognosis, and 
therapy. Further analyses of high-dimensional data from this study may allow the design of 
specific therapeutic strategies against two types of MCC with different phenotypes (Paper 
III).  
Update information 
Exosomes are small bilayer proteolipid vesicles secreted by a variety of cell types, including 
MCC cell lines. Their sizes vary from 30-250 nm in diameter (Paper I and II). In Paper I, 




MCPyV-positive cell lines such as MKL1 and MKL2 resulted in the identification of 172 
common microvesicular proteins of 500, 325, 258, and 228 proteins from MCC13, MCC26, 
MKL1, and MKL2, respectively. Variables of identified proteins’ number explain the proteins 
expression variation between the cell lines and heterogeneity of human cancer [130]. The 
overlap with the Top 100 protein markers was about 69% (MCC13), 49% (MCC26), 47% 
(MKL1), and 39% (MKL2), and includes 37 exosomal markers (Paper I).  
Five hundred thirteen biological pathways were composed of 114 proteins of 164 were 
mapped in the total network (Paper I). Cellular components comprise exosomes (71.2%), 
lysosome (43.6%), proteasome complexes (6.7%), and proteasome core complex (1.8%) with 
significance level P<0.001. Proteins from the extracellular region (33.7%, P<0.001) of Merkel 
carcinoma cell lines presuppose to located on the surface of EVs (Paper I). They might be 
potential biomarkers of MCC surface and proteins that recipient cells recognize, which allow 
the design of targeted treatment. Many of the exosomal proteins associated with metastasis 
and tumorigenesis/tumor progression: fibronectin [131, 132], thrombospondin [133], and 
laminin β1 [134]. Several of EVs proteins exploited as a therapeutic target: α-2-macroglobulin 
[135] and SERPINF1 [136], and others such as mannan-binding lectin serine peptidase 1 had 
an impact on the severity of disease in for example HCV infection [137] (Paper I). We 
identified the lactate dehydrogenase B at subnetwork mTOR pathway [130], and several 14-
3-3 proteins at p75(NTR)-mediated signaling, p38 MAPK signaling and Wnt-pathway [138] 
(Paper I). The majority of proteins showed a positive association with autosomal dominant 
(P<0.001, Paper I). Chromosomal instability and loss of heterozygosity (LOH) are crucial steps 
in tumorigenesis [139]. The ranking of the EV proteins included in the network according to 
the enrichment analysis expressed in urine (89.0%), cerebrospinal fluid (73.0%), amniotic 
fluid (57.1%), saliva (49.1%), and tears (44.8%) with significance level P<0.001 (Paper I). The 
body fluids provide condition-specific biomarkers, which a potential source for diagnostic and 
development of targeted therapy [140, 141]. 
The computational analyses platform development gives us the opportunity to re-analyzed 
the raw data from the first study of exosomal proteomic profiling. In total, 311 proteins 




performed hierarchical clustering to identify groups of samples with similar global protein 
expression profiles (Figure 4).  
 
Figure 4. The dendrogram shows the hierarchical relationship between the samples with similar global protein 
expression profiles. The MCPyV-negative cell lines’ exosomes are MCC13exo, MCC26exo, and the MCPyV-




represents one protein/protein gene. In the box depicted differentially expressed proteins/protein genes 
involved in extracellular matrix and structure organization. 
 
The differences in protein expression visualized in a principal components analysis (PCA) 
projection (Figure 5). The exosome from MCC cell lines formed different groups indicating 
that origin cells are distinct from each other. 
 
Figure 5. Two groups of different samples are exosomes originated from the MCPyV-negative and -positive cell 
lines, which depicted in a principal components analysis (PCA) projection. 
 
In the PCA depicted differences due to origin cells are morphological, genetically and cultured 
discrepant [32, 45] (Paper III). In line, a small number of proteins was uniquely differentially 
expressed between the exosome from MCPyV-negative and –positive MCC cell lines, depicted 
in Figure 4. Exosomes from MCPyV-negative MCC cell lines have upregulated proteins 
involved in biological pathways the extracellular structure (P = 9.39E-08) and extracellular 
matrix (P = 9.39E-08) organization, included 22 proteins (Supporting Information, Table S2).  
Nine exosomal proteins identified as biomarkers in different types of cancer, mesenchymal 
stem cells transition, and post-transcriptional regulation of gene expression, including the 
laminin subunit alpha-4 (LAMA4), fibulin-1 (FBLN1), transforming growth factor beta-1 
(TGFB1), transforming growth factor beta-2 (TGFB2), annexin A2 (ANXA2), decorin (DCN), 
metalloproteinase inhibitor 1 (TIMP1), tenascin (TNC) and versican core protein (VCAN) [142-




growth factor beta-2, annexin A2, and decorin expressed in MCC cell lines and their exosomes 
(Supporting Information, Table S3; Paper I and III). The increased expression of annexin A2, 
transforming growth factor beta-1 and -2 found in polyomavirus-negative MCC cell lines and 
their exosomes compared to virus-positive MCC cell lines and their exosomes. Also, the 
increased expression of fibulin 1 and decorin in exosomes from MCPyV-negative MCC cell 
lines observed. All proteins imply on the cell motility, signal transduction, endocytosis, 
exocytosis, activation for degradation of extracellular matrix (ECM) and basement proteins 
(BM) for cancer cell invasion and metastasis [143, 145, 146, 149, 150, 154, 155] (Paper I and 
III). These results agree with our finding in Paper III, and the MCPyV-negative MCC is 
aggressive cancer with resistance to anticancer drugs, shorter disease-free survival and worse 
overall survival [156, 157]. In addition, the result indicates a crucial role of exosomes as a 
messenger vehicle between cancer and healthy cells in the intercellular signaling in MCCs. 
Exosomes contain cytosolic components, such as proteins, lipids, DNAs, RNAs, including 
mRNAs and microRNAs. In Paper II, the presented research proved that exosomes are stable 
in body fluids, including serum/plasma, and they can be isolated and preserved in PBS for 
long-term at -80 degrees [158]. In total, 519 miRNAs showed differential expression between 
two groups (Paper II). The finding showed that the miRNA existent patterns were not 
homogenous among the same cancer cell types, and exosomes of MCC cell lines contain a 
unique expression profile of miRNAs (Paper II).  
Eight miRNAs such as miR-31-5p, miR-125b-1-3p, miR-143-3p, miR-222-3p, miR-584-5p, miR-
141-3p, miR-375 and miR-532-5p selected based on their involvement in MCCs and other 
tumor types for further validation on serum/plasma samples from healthy donors and MCC 
patients by the qRT-PCR-based method. The qRT-PCR result confirmed the result from NGS 
that exosomal miR-222-3p upregulated in MCPyV-negative MCC cell lines. Moreover, the 
difference was statistically significant between the miR-222-3p expression levels in the 
exosomes from MCPyV-negative and -positive MCC cell lines (Paper II). There is evidence that 
the miRNA-222-3p promotes tumor cell migration and invasion and inhibits apoptosis, and it 




results mentioned above of the exosomal proteomic study and the selectivity of miR-222-3p 
in exosomes [159] (Paper I and II).  
Also, the exosomal miR-222-3p presented at a higher level in healthy condition than in 
pathophysiological state (Paper II). In the early studies, the plasma miR-222-3p identified as 
a robust intrinsic reference miRNA useful for the research of estrogen-responsive miRNAs in 
pregnancy [160]. The other study concluded that there was no significant difference in the 
designation of miRNAs between plasma and plasma-derived exosomal miRNAs, but the 
frequency was higher in plasma in healthy people [161].  
Further, the investigation of exosomal miR-222-3p expression changes in progress upon viral 
and cancer status showed the statistically significant difference between the fold change in 
miR-222-3p expression in exosome samples from healthy donors and patients in relation to 
the MCC MCPyV-negative cell line (Paper II). This result indicates that the level of miR-222-
3p in exosomes dropped down dependent on cancer and viral status of MCC in the circulation 
system, which may lead that target genes can become overexpressed distantly in recipient 
cells on higher proportion vid MCPyV-negative MCC and less vid MCPyV-positive MCC. There 
is evidence that the downregulation of miR-222-3p and upregulation of its target gene poly 
[ADP-ribose] polymerase 1 (PARP1) in the triple negative breast cancer patients associated 
with poor prognosis [162].  
MiR-222-3p predicted target genes from three different databases (ExoCarta, TargetScan, 
and miRTarBase) showed 20 common targets (Paper II). The enrichment analysis showed that 
they expressed in leukocytes. The cancer cells and their exosomes likely interfere with the 
induction of an efficient immune response via several mechanisms inducing triggering T cell 
suppression mechanisms, attenuating NK cell cytotoxicity, and engaging pro-metastatic 
inflammatory processes and generating an immunosuppressive environment to escape from 
the immune system and eventually, treatment failure [163, 164]. Initially revealed that the 
exosomal miR-222-3p derived from epithelial ovarian cancer induces polarization of tumor-
associated macrophages [165].  
Further, transferred exosomal miR-222-3p into subcellular sites in recipient cells induced 




family, which is a major negative regulator of cytokine signaling that regulates development, 
subsets profiling and function of immune cells in carcinogenesis [167].  
Moreover, the exosomal miR-222-3p demonstrated malignant characteristics and function 
such a regulator of gemcitabine resistance by targeting suppressor of cytokine signaling 3 
(SOCS3) [166]. Further study, the hepatitis C virus (HCV) related immuno-pathogenesis found 
to be miR-222-3p enriched in exosomes from patients, which markedly reduced by direct-
acting antiviral (DAA) therapy that consistent with our finding (Paper II). Exosomes from HCV 
patients inhibited natural killer cells (NK) degranulation activity and this effect correlated with 
the exosomal miR‐222‐3p level [168].  
MiR-222-3p has described neither in tissues nor in cells from MCCs that support selectivity of 
exosomal miRNAs, particularly miR-222-3p [169-171]. Also, the enrichment analysis showed 
the predicted 6 of 20 common miR-222-3p targets expressed in MCC cell lines (Paper II and 
III). There are sorting nexin 4 (SNX4), Sad1 and UNC84 domain containing 2 (SUN2), stathmin 
1 (STMN1), 14-3-3 protein gamma (YWHAG), RNA binding protein S1 (RNPS1), and 
karyopherin alpha 2 (KPNA2) identified as differentially expressed proteins in MCC cell lines 
(Supporting Information, Table S4; Paper I, II, and III). Also, MCPyV-negative MCC cell line 
showed have upregulated protein expression on immune system process pathway (P = 2.64E-
06), including 162 proteins (Supporting Information, Table S5; and Paper III). 
There is a clear implication of exosomal miR-222-3p in the immunopathogenesis of MCCs. 
The sorting nexin 4, inner nuclear membrane protein SUN2, and RNA binding protein with 
serine-rich domain 1 were never mentioned to be associated with MCCs, but a stathmin 1 
associated with MCPyV ST antigen, which mediates microtubule destabilization to promote 
cell motility and migration in MCCs [172, 173] (Paper II and III). The karyopherin alpha 2 
induced expression found in MCCs and it is essential for ribosomal RNA (rRNA) transcription 
and protein synthesis in proliferating keratinocytes [174] (Paper II and III). Interestingly, MCC 




protein gamma is one of the oncogenic Wnt pathway’s activation factor, and an additional 
factor of PI3/Akt/beta-catenin signaling on cell proliferation [176, 177].  
Recently, Chu and colleagues showed that level of miR-222 in the patient's group was 
significantly lower than in the healthy group, and their over-expression decreased cell 
proliferation and invasion in osteosarcoma [178]. This result agrees with our investigation 
result (Paper II). Moreover, reduced miR-222 promoted YWHAG expression and up-
regulation of YWHAG restored the inhibiting effect of miR-222 mimics [178]. Wei and 
colleagues study of exosomal miR-222-3p concluded that a higher level of this exosomal 
miRNAs in serum usually predicted worse prognosis in non-small cell lung cancer (NSCLC) 
patients [166]. It can applyed to the cancer environment since MCPyV-negative MCC cell 
lines’ exosomal miR-222-3p level higher compared the level in MCPyV-positive cell lines, and 
MCPyV-negative MCC patients have worse outcomes [19, 179] (Paper II). Thus, the result 
indicates the exosomal miR-222-3p and its targets play a pleiotropic role in MCC 
tumorigenesis and drug resistance. 
Several MCC cell lines are available, but little has been done to characterize MCC cell lines 
phenotype. In Paper III (PXD012909), we analyzed global proteomics in seven MCC cell lines: 
the MCPyV-negative cell lines such as MCC13, MCC26, and UISO and the MCPyV-positive MCC 
cell lines such as MKL1, MKL2, MS1, and WaGa. In all samples, we identified 4898 proteins in 
total (Paper III). We performed statistical validation between each sample and each group of 
cell lines: MCC13, MCC26, UISO, and MKL1, MKL2, MS1, and WaGa, and as MCPyV-negative 
and –positive cell lines, respectively. In total, 3312 proteins of 4898 identified showed 
differential expression between two groups (Paper III). Guastafierro and colleagues identified 
differences in various diagnostic markers for MCCs between MCPyV-negative and –positive 
cell lines by immunohistochemistry analysis (IHC) [45] (Paper III). According to another study, 
the IHC diagnostic panel includes the neurofilament as a positive marker also [46]. In 
comparison to data published previously, this study is the proteomic profile, and sample 
expanded to include WaGa (Supporting Information, Table S6.A, and S6.B; and Paper III). We 
found in all samples expressed cytokeratin 20, pan-keratin, cytokeratin 1, cytokeratin 8, 




of unique peptides for cytokeratin 7 (CK7) compare to other cell lines, except MKL1, which is 
negative for CK7. Synaptophysin expressed only in MCPyV-positive cell lines, and all cell lines 
are negative for leukocyte common antigen and thyroid transcription factor 1.  
Also, we looked for all neurofilament subunit proteins and corresponded to the previous 
study result [46]. Our study showed the MCPyV-positive MCC cell lines have a high number 
of unique proteins for the low molecular weight neurofilament protein (FN-L) compared to 
MCPyV-negative MCC cell lines. This result agrees with the previous study result (Supporting 
Information, Table S6.C). Further, MCPyV-positive MCC cell lines expressed a high number of 
unique peptides for the medium molecular weight neurofilament protein (NF-M) and 
neuronal intermediate filament proteins, alpha-internexin compared to MCPyV-negative cell 
lines. MCPyV-negative MCC cell lines are negative for the high molecular weight 
neurofilament protein (FN-H). The peripherin is negative in MCC13, MCC26 and WaGa, and a 
high number of unique peptides found in MKL2. A high amount of neuronal intermediate 
filament protein, nestin, found in MCC13 and UISO.  
Finally, we investigated expression of neural cell adhesion molecule 1 (NCAM1), ubiquitin C-
terminal hydrolase 1 (PGP9.5/UCHL1), oncoprotein hunting-interacting protein 1 (HIP1), 
epithelial cell adhesion molecule (EpCAM), and vimentin (VIM) mentioned in other studies 
[15, 45-49] (Supporting Information, Table S6.D). The neural cell adhesion molecule 1, 
ubiquitin C-terminal hydrolase 1, and oncoprotein hunting-interacting protein 1 upregulated 
in MCPyV-positive cell lines compared to MCPyV-negative MCC cell lines. The vimentin over-
expressed in MCPyV-negative MCC cell lines compared to MCPyV-positive MCC cell lines. The 
only epithelial cell adhesion molecule is uniquely expressed in MCPyV-positive cell lines 
(Paper III). 
Results consistent with the IHC diagnostic panel and other MCC markers’ studies, but with 
the proteomic approach was detected even a small amount of proteins in samples, and 
proteins expression differentiates cell types. The result confirmed that the proteomic method 
is the more sensitive approach for cells phenotyping and exploring biomarkers. 
We performed hierarchical clustering to identify groups of samples with similar global protein 




divergent from the MCPyV-positive cell line, indicating that these cell lines are distinct from 
each other. These differences in protein expression can also be visualized in a principal 
components analysis (PCA) projection (Paper III). The result supports previous comparative 
studies between MCC cell lines [45, 180]. In line, many proteins uniquely differentially 
expressed between the MCPyV-negative and –positive MCC cell lines. The Spearman’s rank 
correlation coefficients between individual expression profiles of MCC cell lines calculated to 
find the relationship in protein expression between MCPyV-negative and –positive MCC cell 
lines. The result showed a strong, positive correlation, r = 0.70, n = 9, P = 0.0433 (Paper III).  
Two major clusters with a size of 1510 and 1170 proteins differentially expressed between 
MCPyV-negative and –positive MCC cell lines include 61  (Supporting Information, Table S7) 
and 46  (Supporting Information, Table S8)  biological pathways upregulated with MCPyV-
negative and -positive MCC cell lines, respectively (Paper III). Proteomic profile revealed MCC 
cellular and molecular mechanisms of carcinogenesis and metastasis. MCPyV-positive MCC 
cell line cells had up-regulated proteins involved in cellular pathways among epigenetic 
regulation of gene expression (P = 5.83E-07), histone modification (P = 2.82E-04), gene 
silencing (P = 6.46E-04), and transcription from RNA polymerase II promoter (P = 5.15E-06) 
(Supporting Information, Table S9). In addition, data indicates that they have active control 
over DNA replication (P = 1.89E-12), DNA recombination (P = 8.15E-09), DNA modification (P 
= 1.11E-03), DNA-dependent transcription termination (P = 1.73E-04), DNA repair (P = 3.52E-
07), and DNA ligation (P = 8.93E-03) (Supporting Information, Table S10). These actions are 
essential at single and double breaks in duplex DNA molecules and proliferating cells. MCPyV-
positive MCCs have a low mutational burden, which explained by high activity and regulation 
of transcriptional, translational and repair system [181].  The increased demand for DNA 
synthesis required on one-carbon (P = 3.01E-03), nucleobase-containing (P = 7.94E-22), 
cellular nitrogen compound (P = 7.08E-22), and nitrogen compound (P = 1.43E-20) metabolic 
processes for the proliferative cancer phenotype [182-184] (Supporting Information, Table 
S11). Upregulated nitrogen metabolic processes indicate that glutamine and asparagine (P = 
2.64E-03) use for supporting high proliferative polyomavirus-transformed cells [183] 




support the rapid cell proliferation [185, 186]. This so-called Warburg effect seems to apply 
for MCPyV-positive MCC cell lines because they have upregulated expression of proteins 
involved in oxidative phosphorylation (P = 4.06E-03), particularly the NADH dehydrogenase 
complex (P = 1.87E-05) associated with mitochondrion (P = 1.05E-02) (Supporting 
Information, Table S12). An active transforming cell phenotype requires high energy. Lactate 
dehydrogenase B (LDHB) catalyzes the reversible conversion of lactate to pyruvate, and NAD 
to NADH, in the glycolytic pathway. With NADH accumulation decreased mitochondrial 
oxidative phosphorylation [187]. Cells that have a greater impairment of oxidative 
phosphorylation and high NADH production become more aggressive and metastatic 
phenotypes like the MCPyV-positive MCC [187]. In contrast, the MCPyV-negative MCC cell 
lines profile indicates that cells’ metabolism switched to amine (P = 1.57E-03), polysaccharide 
(P = 8.61E-03) and carbohydrate (P = 4.20E-03) metabolic processes for cell growth (P = 1.05E-
02), proliferation (P = 4.99E-03) and differentiation (P = 1.64E-03) (Supporting Information, 
Table S13). Polyamines play a pleiotropic role, from modulating nucleic acid conformation to 
promoting cellular proliferation and signaling (signal transduction, P = 4.55E-06; Supporting 
Information, Table S14). [188]. Lipid particles (P = 7.49E-03) indicate ongoing energy store 
and a repository of fatty acids for potentially phospholipid biosynthesis [189] (Supporting 
Information, Table S15). Moreover, proteins involved in cell motility (P = 4.40E-04), 
maintenance of cell polarity (P = 5.47E-03), cell surface (P = 4.05E-09), locomotion (P = 9.57E-
05), and cellular membrane organization (P = 7.49E-04) were upregulated indicating high 
invasiveness and metastasis of the MCPyV-negative MCC cells [190] (Supporting Information, 
Table S16, Paper I, II and III). Post-translational modification such as protein glycosylation (P 
= 1.04E-05), peptidyl-amino acid modification (P = 2.05E-04), protein folding (P = 4.86E-03), 
and protein modification process regulation (P = 5.24E-03) were observed (Supporting 
Information, Table S17). Upregulation of protein glycosylation of surface molecules showed 
a key feature of cancer cells, which use the endoplasmic reticulum (ER, P =1.35E-08)/Golgi 
apparatus (P = 1.28E-03) to add carbohydrates to their cumulative glycoproteins [191] 
(Supporting Information, Table S18). Thus, data indicates that the MCPyV-negative MCC cell 




have upregulated proteins engaged in post-translational modification. In these 
circumstances, cancer progression and high cell proliferation may lead to transcription-
associated mutation (TAM) and transcription-associated recombination (TAR) that gave a rise 
a high mutational burden of MCPyV-negative MCC [181, 192-194].  
We reused the previous study of proteomic data for integrated analysis and researched 
Merkel cell polyomavirus proteins in exosome samples from MCPyV-positive MCC cell lines 
(PXD004198, Paper I). Computational approach developments and ongoing proteomic 
studies of oncogenic viruses, particularly MCPyV, give us the opportunity to detect MCPyV 
proteins in MCPyV-positive MCC cell lines and their extracellular vesicles (Paper III).   
Exosomes derived from virus-positive MCC cells are not only packed with cellular compounds, 
but they also contain viral protein fragments of large T antigen, LT chain E, small T antigen, 
major capsid protein VP1, and minor capsid protein VP2 (MKL2 exosomes). Also, integrated 
data of cellular and extracellular vesicles proteomic profiles showed that the cellular 
endosome transport and extracellular vesicles contain proteins involved in viral reproduction 
( P = 1.39E-03) similarly abundant in both MCC cell lines and their exosomes, but upregulated 
in MCPyV-positive cell lines (Supporting Information, Table S19). However, upregulated 
proteins involved in endocytosis (P = 3.27E-06), exocytosis (P = 9.04E-03), vesicle-mediated 
transport (P = 8.24E-10), Golgi vesicle transport (P = 2.31E-05) and protein transport (P = 
4.69E-03) were associated with MCPyV-negative MCC cell lines (Supporting Information, 
Table S20).  
Except that, exosomes from MCPyV-negative cell lines were most abundant with extracellular 
vesicles-ER accession proteins. In contrast, the valosin-containing protein (VCP), aconitase 1 
(ACO1) and argininosuccinate synthase 1 (ASS1) were only proteins detected in extracellular 
vesicles from MCPyV-positive cell lines. The valosin-containing protein required for the fusion 
of ER and Golgi membranes. The valosin-containing protein is a membrane ATPase involved 
in ER homeostasis and ubiquitination [195, 196]. The aconitase 1 is the moonlighting protein 
based on its ability to perform mechanistically distinct functions. One of the aconitase 1 
ability is to bind glucose-regulated protein 94 kDa (Grp94), which is the ER-localized isoform 




Toll-like receptors, immunoglobulins, and integrins [197]. The argininosuccinate synthase 1 is 
a key enzyme in the citrulline-nitric oxide (NO) cycle, which can be upregulated by nitrogen 
efflux at Kaposi’s sarcoma-associated herpesvirus (KSHV) infection and an acid-induced 
downregulation contributes to the maintenance of intracellular pH in cancer [198, 199]. 
Evolutionary, exosomes maintain cellular homeostasis by carrying cellular remains from the 
misfolded proteins loaded on the ER through the Golgi and subsequently remove these waste 
products by exocytosis to prevent genotoxic conditions [63]. Data analysis suggests that 
MCPyV use the functional exosome secretion for their promotion through to ability packed 
exosomes in a certain condition with virus proteins, which end up in ER as misfolded proteins. 
The preserved virus protein in an exosome can proceed on the way to out of cells. Thus, 
extracellular vesicles as a cellular communication’s mediators help facilitate the transfer of 
viral compounds to new cells in a cancer environment or/and distantly to recipient cells and 
promote pathogenic processes [200]. 
Limitations 
These project findings require further evaluation studies. Development of methods with 
higher discovery power gives the rise the requirement to choose experimental methods to 
evaluate the result. Experimental validation of identified biomarkers in a completely 
independent data set representing an appropriate experimental system provides reliable, 
high-quality evaluation, but it costs and requires time. 
Privacy and Ethics 
In Paper II, the clinical samples from MCC patients used. The Ethics Committee of Karolinska 
Institutet approved the study, and all patients provided informed consent in written form. 
This thesis content TEM pictures generated in collaboration with the Institute of Medical 
Biology, Core Facility of Advanced Microscopy, University of Tromsø, The Arctic University of 








6    Chapter: Conclusions 
The Paper I conclusion is our results showed that MCPyV-negative and –positive Merkel cell 
lines’ exosomes contain several proteins associated with tumor cell motility and metastasis. 
Importantly, we identified a list of vesicular proteins derived from the extracellular region, 
which upregulated in exosome from MCPyV-negative MCC cell lines compare to MCPyV-
positive MCC cell lines. They could reveal biomarkers specific for MCCs identification and 
exosomes recognition proteins by target and recipient cells.  
 
The Paper II conclusion is our results showed that the exosomal miR-222-3p presence in all 
type of samples derived from MCC cell lines, healthy donors and MCC patients. There was a 
statistically significant difference between the miR-222-3p levels in the exosome samples 
from MCPyV-negative and -positive MCC cell lines. MCPyV-negative MCC cell lines’ exosomal 
miR-222-3p was a higher level than MCPyV-positive MCC cell lines. The miR-222-3p 
selectively sorted, and its expressed level dropped down dependent on cancer and viral 
status in MCC patients in the circulation system. The target genes’ scanning indicates that the 
exosomal miR-222-3p play pleiotropic role dependent on recipient cells in health and disease. 
Exosomes derived from MCC may imply cell-to-cell communication within the tumor 
environment and the circulation system. They appear to transport specifically sorted 
functional proper such as miRNAs as messengers to target and recipient cells. 
 
Finally, the Paper III conclusion is a proteomic approach is a powerful tool for cell 
phenotyping and biomarkers discovery. To understand the underlying mechanisms of virus-
independent and virus-dependent MCCs, we compared the proteome of MCPyV-negative 
(MCC13, MCC26, and UISO) and MCPyV-positive (MKL-1, MKL-2, MS-1, and WaGa) MCC cell 
lines. In total 4898 proteins were identified, of which 3312 differentially expressed between 
the virus-negative and virus-positive cell lines. Then, the MCPyV-negative MCC cell lines 
indicates to loss DNA, RNA and protein synthesis and their regulation system activity, and 
have an unusual event of protein expression at cell proliferation and post-translational 




transcription-associated recombination (TAR), which gave a rise a high mutational burden. 
The MCPyV-positive MCC cell lines showed upregulated expression of proteins involved in 
DNA transcription initiation, termination, and repair, may harnesses of polyomaviruses for 
DNA integration. Following upregulated proteins of RNA, protein synthesis and modification 
machinery such as the protein acylation culminates in the viral proteins and genome 
synthesis. However, a fixed exosome-ER accession ability and a low activity on endocytosis 
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Extracellular vesicles or exosomes constitute an evolutionarily conserved mechanism of inter-
cellular signaling. Exosomes are gaining an increasing amount of attention due to their role
in pathologies, including malignancy, their importance as prognostic and diagnostic markers,
and their potential as a therapeutic tool. Merkel cell carcinoma (MCC) is an aggressive form of
skin cancer with a poor prognosis. Because an effective systemic treatment for this cancer type
is currently not available, an exosome-based therapy was proposed. However, comprehensive
secretome profiling has not been performed for MCC. To help unveil the putative contribution
of exosomes in MCC, we studied the protein content of MCC-derived exosomes. Since approx-
imately 80% of all MCC cases contain Merkel cell polyomavirus (MCPyV), the secretomes of
two MCPyV-negative and two MCPyV-positive MCC cell lines were compared. We identified
with high confidence 164 exosome-derived proteins common for all four cell lines that were an-
notated in ExoCarta and Vesiclepedia databases. These include proteins implicated in motility,
metastasis and tumor progression, such as integrins and tetraspanins, intracellular signaling
molecules, chaperones, proteasomal proteins, and translation factors. Additional virus-negative
and virus-positive MCC cell lines should be examined to identify highly representative exosomal
proteins that may provide reliable prognostic and diagnostic biomarkers, as well as targets for
treatment in the future. Data are available via ProteomeXchange with identifier PXD004198.
Keywords:
Cancer / Cell biology / Exosome / Merkel cell carcinoma / Polyomavirus
 Additional supporting information may be found in the online version of this article atthe publisher’s web-site
Merkel cell carcinoma (MCC) is an aggressive skin cancer of
neuroendocrine origin, with a mortality rate >50% [1]. Feng
et al. identified a previously unknown polyomavirus that was
integrated in eight out of ten examined MCC samples [2].
They referred to this novel virus as Merkel cell polyomavirus
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(MCPyV), and worldwide studies have confirmed that approx-
imately 80% of MCC contain integrated viral DNA [3,4]. Cell
culture and animal studies have confirmed the oncogenic
properties of MCPyV [5,6], with MCPyV classified as a poten-
tial oncogenic biological agent in MCC [7]. Besides surgical
excision and postoperative radiotherapy, no effective systemic
treatment for this cancer type is yet available [8].
Exosomes are small bilayer proteolipid vesicles secreted by
a variety of cell types [9]. Their sizes vary from 30 to 100 nm
in diameter [10] or slightly larger up to 150 nm [11, 12]. Ex-
tracellular vesicles (EVs) contain cytosolic components [13];
however, the composition, biogenesis, and secretion of exo-
somes are influenced by the surrounding environment and
cellular conditions [14].
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Table 1. The exosomes (n = 3) size distributions were determined
by photon correlation spectroscopy on a submicron par-
ticle sizer model 370, and are represented in intensity-
weight distribution






MCC13 29 ± 3 32 104 ± 5 66 0.37
MCC26 29 ± 5 36 134 ± 8 63 0.33
MKL1 36 ± 5 55 126 ± 8 44 0.36
MKL2 31 ± 4 39 158 ± 7 61 0.38
a) Polydispersity index.
Exosomes have gained increasing attention for their in-
volvement in the pathogenesis of several diseases, includ-
ing cancer. Virus-infected cell-derived vesicles are not only
packed with cellular compounds, but also contain viral
proteins and nucleic acids [15]. This may help facilitate
the transfer of viral compounds to new cells and pro-
mote pathogenic processes [16, 17]. Intercellular signaling
mediated by EVs or exosomes is an evolutionarily conserved
phenomenon [18, 19]. Furthermore, exosomes can also be
recognized by antigen-presenting cells, and cell-to-cell me-
diated immune activation can result in antitumor responses
[20,21]. Exosome-based vaccines have been developed for can-
cer therapeutics [22], and to help assess the possible role of
MCC-generated exosomes in tumorigenesis we investigated
whether MCC cell lines produce exosomes, and we compared
the protein content of exosomes secreted by two different
MCPyV-negative, such as MCC13 and MCC26, and two dif-
ferent MCPyV-positive cell lines, such as MKL-1 and MKL-2,
respectively.
EVs were isolated from Merkel carcinoma cell lines by a
series of differential centrifugation, filtration, and the use of
the ExoQuick exosome precipitation reagent. All experiments
were run in triplicate, while the collection of EVs and their
characterization were done from 10 mL of supernatant. The
Submicron Particle Size Analyzer showed the vesicular struc-
tures of these purified EVs with a diameter range of 30–150
nm (Table 1). The transmission electron microscopy con-
firmed this result, which is in agreement that EVs within the
range of 30–150 nm are cup-shaped vesicles (Fig. 1A: in box
and B: arrow heads), and that those smaller than 30 nm or
larger than 150 nm EVs are apoptotic blebs and shedding mi-
crovesicles, respectively, as previously reported [12,23]. More
experimental details are provided in the Supporting Informa-
tion.
For Merkel carcinoma cell lines, the identification of EV
protein peptide mixtures containing formic acid was loaded
onto a Thermo Fisher Scientific EASY system. Peptides were
fractionated, and separated peptides were analyzed using a
Thermo Scientific Q-Exactive mass spectrometer. Data were
collected in a data-dependent mode using a Top10 method
[24]. The fragmentation spectra were searched against the
UniprotKB Homo Sapiens 2016/02/29 database using an in-
house MASCOT server. The raw data were processed using
Proteome Discoverer 1.4 software. Peptide ions were then
filtered using a FDR set to 1% for further peptide identifi-
cation. The secretome profiling of two MCPyV-negative cell
lines, MCC13 and MCC26, and of the MCPyV-positive cell
lines, MKL1 and MKL2 [25, 26], resulted in the identification
of 172 common microvesicular proteins of 500, 325, 258, and
228 identified proteins from MCC13, MCC26, MKL1, and
MKL2, respectively (Fig. 2A). The variables of identified pro-
teins’ number explain the proteins’ expression variation be-
tween the cell lines [27], as well as the heterogeneity of human
cancer [28], patient-to-patient variation [12], and the identifi-
cation of proteins in our proteome derived from replicative
Q-Exactive MS analyses (n = 3).
To compare our Merkel cell lines EV dataset with other
studies, we performed an enrichment analysis using Exo-
Carta v5 [29], Vesiclepedia v3 [30] protein databases, and The
FunRich v2.1.2 [31] open access tool. The total list of proteins
from exosomes displayed an approximate 94% overlap with
Figure 1. Characterization of Merkel cells and their exosomes
by transmission electron microscopy, ×80 000 magnification. (A)
Merkel cells releasing and exchanging vesicles (in box) via jux-
tacrine cell–cell communication. Scale bar = 1 m. (B) A section
of purified exosomes produced using the malachite green proto-
col and size was confirmed by EVs of 30–150 nm (arrow heads),
which are displaying a cup-shaped morphology characteristic of
exosomes. Scale bar = 500 nm.
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Figure 2. Comparison analysis of MCPyV-negative and MCPyV-positive Merkel cell lines secretomic proteins. (A) Venn diagram of the
overlap between the four cell lines. Enrichment analysis of cellular components localization (B), biological pathways (C), clinical phenotypes
(D), and site of expression (E) of common proteins from this study over FunRich database as background.
C© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com
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ExoCarta and an approximate 99% overlap with Vesiclepedia.
The overlap with the top 100 protein markers is approximately
69% (MCC13), 49% (MCC26), 47% (MKL1) and 39% (MKL2),
respectively.
From 172 proteins, 164 proteins were annotated in Exo-
Carta and Vesiclepedia databases (Supporting Information
Table 1). These common cargo proteins include 37 exosomal
markers (Supporting Information Table 2). Cellular compo-
nents comprise exosomes (71.2%), lysosome (43.6%), pro-
teasome complexes (6.7%) and a proteasome core complex
(1.8%) with a significance level p < 0.001. Proteins from ex-
tracellular region (33.7%, p < 0.001) of Merkel carcinoma cell
lines presuppose to be located on the surface of EVs (Fig. 2B
and Supporting Information Table 3). They might be poten-
tial biomarkers of MCC surface and proteins that recipient
cells recognize, which allow the design of targeted treatment.
Many of the exosomal proteins are associated with metastasis
and tumorigenesis/tumor progression, including fibronectin
[32,33], thrombospondin [34], and laminin 1 [35]. Several of
the EVs proteins were exploited as a therapeutic target: alpha-
2-macroglobulin [36] and serpin peptidase inhibitor, clade F,
member 1 [37], while others such as mannan-binding lectin
serine peptidase 1 have an impact on the severity of disease
in, e.g. hepatitis C virus infections [38].
Interestingly, we identified the lactate dehydrogenase B at
subnetwork mechanistic target of rapamycin pathway [39],
and several 14-3-3 proteins at p75(NTR)-mediated signaling,
p38 MAPK signaling, and the Wnt pathway [40] (Fig. 2C and
Supporting Information Table 4). The majority of proteins
displayed a positive association with autosomal-dominant, ge-
netic processes (p < 0.001, Fig. 2D and Supporting Informa-
tion Table 5). Chromosomal instability and a loss of heterozy-
gosity are important steps in tumorigenesis [41]. The ranking
of the EV proteins included in the network, according to the
enrichment analysis secreted in urine (89.0%), cerebrospinal
fluid (73.0%), amniotic fluid (57.1%), saliva (49.1%), and tears
(44.8%), has a significance level p < 0.001 (Fig. 2E). The body
fluids provide condition-specific biomarkers, with a poten-
tial source for the diagnosis and development of a targeted
therapy [42, 43].
In conclusion, our results show that MCPyV-negative and
MCPyV-positive Merkel cell lines’ EVs contain several pro-
teins associated with tumor cell motility and metastasis. Im-
portantly, we identified a list of vesicular proteins derived
from the extracellular region, which could reveal biomarkers
specific for MCC identification and EVs’ recognition proteins
by recipient cells. Lastly, our comprehensive secretome pro-
file stimulates further studies aiming at the differences and
functions of EVs secreted by MCPyV-negative and MCPyV-
positive Merkel cell lines, respectively.
The MS proteomics data have been deposited to the ProteomeX-
change Consortium via the PRIDE [44] partner repository with
the dataset identifier PXD004198.
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Supporting Information 
Materials and Methods 
Cell Culture 
The human Merkel cell polyomavirus-negative cell lines MCC13 and MCC26 
and polyomavirus-positive Merkel cell carcinoma cell lines MKL-1 and MKL-
2 were a kind gift from Dr B. Akgül (Institut für Virologie Uniklinik Köln, 
Köln, Germany). All cell lines were kept in culture medium RPMI-1640 
(Sigma-Aldrich, Oslo, Norge) supplemented with 10% exosome depleted 
fetal bovine serum (Exosome-depleted FBS, System Biosciences, 
Cambridge, UK) for 72 hours. All cell types were incubated in a 5% CO2 
humidified incubator at 37⁰C.  FBS-associated-exosomes were stripped and 
were removed by dilution of FBS in RMPI-1640. Then, a cell suspension was 
collected and centrifuged for 5 minutes at 200 x g to removed whole cells. 
The collected supernatants were centrifuged for 15 minutes at 3000 x g to 
remove dead cells and stored in aliquots at -80 ⁰C.   
Extracellular Vesicles Isolation and Purification 
The supernatants were thawed and centrifuged for 30 minutes at 10,000 x 
g in an centrifuge using a JA-25.50 rotor (Avanti J-26XP, Beckman Coulter 
Inc., Fullerton, CA, USA) to remove cell debris, and subsequently sterile-
filtered using a 0.2 µm filter (Pall Corporation, Ann Arbor, MI, USA). 
Extracellular vesicles were isolated by ExoQuick-TCTM Exosome Precipitation 
Solution (System Biosciences) according to the manufacture’s instruction. 
Briefly, the appropriate volume of ExoQuick-TC Exosome Precipitation 
Solution was added to the supernatant. The mixsture was incubated for 12 
hours at 4 ⁰C and centrifuged at 1500 x g for 30 minutes at room 
temperature. The extracellular vesicles’ pellet was centrifuged (Allegra® X-
15R, Beckman Coulter Inc., Palo, CA, USA) for another 5 minutes at 1500 
x g and the supernatant was removed without disturbing the precipitated 
extracellular vesicles in pellet. 
Transmission Electron Microscopy   
Cells and extracellular vesicles were fixed with 1x fixative consisting of 0.5% 
Glutaraldhyde (Sigma-Aldrich), 4% Formaldehyde (Sigma-Aldrich), and 
0.05% Malachite Green (Sigma-Aldrich) in PHEM-buffer (Sigma-Aldrich) 
and microwaved 14 minutes following the Malachite Green Fix according to 
Valdivia’s lab protocol [1]. After washing, cells and extracellular vesicles 
were dehydrated in graded ethanol solutions. Cells and extracellular 
vesicles were flat embedded with epoxy resin and cured on the coverslip at 
60 °C for 24 h. The flat embedding was cut into small pieces to isolate the 
cells and extracellular vesicles of interest. The pieces were glued on spar 
resin blocs, trimmed close to the cells and extracellular vesicles of interest 
and mounted on an ultra-microtome (Leica, Germany) for sectioning as 
parallel as possible to the resin surface. Serial sections of 60 nm thickness 
were caught with a loop and set down on 75 lines/inch Hexagonal Mesh 
copper/0.7% formvar (Sigma-Aldrich)-coated grids (Electron Microscopy 
Sciences, Chemi-Teknik AS, Oslo, Norge). Sections were observed at 80 kV 
with a JEOL JEM-1010 (JEOL Ltd, Peabody, MA, USA), and images were 
acquired with a digital camera Morada (Olympus Soft Imaging System, 
Münster, Germany). 
Particle Size Analysis 
The particle size distributions of extracellular vesicles was determined by 
photon correlation spectroscopy (Submicron particle sizer model 370, 
Nicomp, Santa Barbara, CA, USA). In order to avoid interference from dust 
particles, the test tubes to be used for the determination were filled with 
distilled water and sonicated for 10 min in ultrasonic bath, then rinsed with 
filtered water (using 0.2 µm filter) prior to the experiments. All formulations 
were prepared in a laminar airflow bench and analyses run in vesicle mode 
and the intensity-weight distribution at 23-24 °C [2]. Three parallels were 
determined (run time at least 25 min) for each sample measurement. 
NuPage Gel Electrophoresis 
Each protein concentration was determined by the Direct Detection method 
(Direct Detect Spectrometer, Merck Life Science AS, Oslo, Norway) as 
described previously [3]. Separation of the exosomal proteins from total 
lysates (30 μg) was performed by 4-12% NuPage Novex (Life Technologies, 
Oslo, Norway).  
Liquid Chromatography-Tandem Mass Spectrometry 
Gel pieces were subjected to in gel reduction, alkylation, and tryptic 
digestion using 6 ng/μl trypsin (V511A, Promega, Wisconsin, USA) [4]. 
OMIX C18 tips (Varian Inc., Palo Alto, CA, USA) were used for sample clean 
up and concentration. Peptide mixtures containing 0.1% formic acid were 
loaded onto a Thermo Fisher Scientific EASY-nLC1000 system and EASY-
Spray column (C18, 2µm, 100 Å, 50µm, 50 cm). Peptides were fractionated 
using a 2-100% acetonitrile gradient in 0.1 % formic acid over 50 min at a 
flow rate of 200 nl/min. The separated peptides was analysed using a 
Thermo Scientific Q-Exactive mass spectrometer. Data was collected in data 
dependent mode using a Top10 method [5]. The raw data were processed 
using the Proteome Discoverer 1.4 software. The fragmentation spectra 
were searched against the UniprotKB Homo Sapiens 2016/02/29 database 
using an in-house Mascot server (Matrix Sciences, UK). Peptide mass 
tolerances used in the search were 10 ppm, and fragment mass tolerance 
was 0.02 Da. Peptide ions was filtered using a false discovery rate (FDR) 
set to 1 % for peptide identifications. 
Data Analysis 
The Exocarta v5 [6] (www.exocarta.og) and Vesiclepedia v3 [7] 
(www.microvesicles.org) databases were used for analysis of MCC cell lines 
specific EVs proteins. The MCC cell lines specific EVs proteins annotated in 
ExoCarta and Vesiclepedia (n = 164) were analysed for enrichment by 
FunRich v2.1.2 [8, 9] (www.funrich.org) open access tool.  
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Abstract: MicroRNAs (miRNAs) are small non-coding RNAs responsible for post-transcriptional 
regulation of gene expression through interaction with messenger RNAs (mRNAs). They are involved 
in important biological processes and dysregulated in a variety of diseases, including cancer and 
infections. Merkel cell carcinoma (MCC) is skin cancer of neuroendocrine origin. The major risk factors 
are ultraviolet light exposure and the presence of integrated Merkel cell polyomavirus (MCPyV) 
genome. In the past few years, evidence of the presence of cellular miRNAs in extracellular human body 
fluids such as serum, plasma, saliva, and urine has accumulated. miRNAs have been found in 
membrane-bound vesicles such as exosomes. Although little known about the role of exosomal 
miRNAs, it has demonstrated that miRNAs secreted by virus-infected cells are transferred to and act in 
uninfected recipient cells, thereby contributing to spreading the pathogenic properties of the virus. I 
this work, we sequenced exosomal miRNAs of MCPyV-negative and –positive MCC cell lines and 
validated on exosomal serum/plasma healthy donors and MCC patients. The result showed the miR-
222-3p is present in exosomes from Merkel cell carcinoma cell culture, serum of healthy donors and 
plasma of MCC patients. 
Keywords: microRNA, exosomal miRNA, Merkel cell carcinoma, Merkel cell polyomavirus, cell line. 
 
1. Introduction 
Merkel cell carcinoma (MCC) is an aggressive and lethal type of neuroendocrine skin cancer [1]. 
MCC is rare, but its incidence is increasing by 95% compared to melanoma and solid tumors [2]. The 
risk of developing Merkel cell carcinoma is greatly increased among a large number of 
immunosuppressed patients [3-6]. Integrated Merkel cell polyomavirus (MCPyV) genome is found in 
~80% of MCC [1]. However, ~20% of MCC tumors do not have detectable MCPyV, which suggest 
alternative etiologies for this tumor type. UV exposure being a major risk factor. The pathogenesis, 
aggressiveness, metastatic potential and response to treatment can be different among individual 
patients with the same kind of cancer that suggest the role of genetic factors in cancer pathogenesis [7]. 
There are needs of personalized treatments of cancer patients. Highly specific biomarkers may provide 
valuable information for diagnosis, prognosis, and therapy [8]. The treatment of MCC depends on many 
factors, but traditionally is the surgical intervention and the adjuvant chemo- and radiation therapy [9]. 
Immune therapy based on monoclonal antibodies targeting the program cell death protein 1 (PD-1) and 
its ligand L1 (PD-1/PD-L1) axis represents a promising approach for cancer treatment in MCC patients 
[10-12]. However, PD-1/PD-L1 therapy has failed to arrest the cancer progression leading to identifying 
pre-existing and acquired mechanisms of resistance to the immune treatment [11-13].  
It is clear that cell-to-cell communication serves an important role in cancer cells adaption and 
survival. Cells can communicate by direct contact via junctions or by secreting signaling molecules that 
are taken up by targets cells. Another mode of communication is by secreting extracellular vesicles 
packed with cargo which are taken up by recipient cells. One type of extracellular vesicles is exosomes 
[14]. Exosomes are membrane vesicles of an average 30 – 300 nm in diameter [15]. They are produced 
by most cells, are stable and can be detected in various body fluids such as serum, plasma, saliva and 
urine that are routinely examined in patients. Exosomes can carry proteins, lipids, sugars, RNA and 
DNA [16, 17]. However, the exosomal contents are unique for the different cell types from which they 
originate. Exosomes play an important role in non-pathogenic and pathogenic processes. The exosomal 
process is perturbed in cancer, and cancer cells secrete more exosomes compare to healthy cells [16]. 
Many studies confirmed that exosomes from different cells types contain a unique expression profile of 
microRNAs (miRNAs), which indicates selectivity of exosomal miRNAs [14, 18-23]. The miRNAs are 
modulators of gene expression. They are approximately 17-24 nucleotide long non-coding RNAs that 
function by targeting messenger RNA (mRNA) leading to their degradation and suppressing protein 
translation at the post-transcriptional level [23-25]. miRNAs involved in every aspect of cellular 
processes such as cell cycle control, proliferation, programmed cell death, immune responses, hormone 
secretions, and angiogenesis through the gene expression regulation [25-29]. 
Furthermore, aberrant expression of the miRNAs profile has been described in various diseases, 
including cancer that they associated with disease stage, cancer subtype and drug resistance [30-36]. 
Exosomes and miRNAs are detectable in various body fluids such as serum, plasma, saliva, and urine. 
Moreover, the levels of exosomes and miRNAs differ between healthy donors and cancer patients [24]. 
Thus, exosomal miRNAs are important as messengers in cell-to-cell-communication [37]. 
In the current study, the exosomal microRNAome from MCPyV-negative and –positive MCC cell 
lines compared by next-generation sequencing (NGS). The presence of one differentially expressed 
miRNA, miR-222-3p was validated in exosomes from Merkel cell carcinoma cell culture and in serum 
samples from healthy donors and plasma from MCC patients. Furthermore, putative target genes and 
the role of miR-222-3p as the messenger in cell-to-cell communication in the cancer environment and 
the circulation is discussed 
2. Results 
2.1. Characterization of Exosomes from MCPyV-Negative and -Positive Merkel Cell Carcinoma Cell Lines 
Exosomes were isolated from the MCPyV-negative cell lines MCC13, MCC26, and UISO, and the 
MCPyV-positive cell lines MKL1, MKL2, and WaGa. The purified exosomes were evaluated by size, 
protein markers, and electron microscopic appearance. 
The diameter of exosomes is considered to be between 30 and 300 nm [15, 38]. The size distribution 
of the exosomes isolated from the six MCC cell lines was determined by photon correlation spectroscopy 
and showed that the mean diameter size of exosomes from MCPyV-negative MCC cell lines was in the 
range between 25.1 ± 2.6 and 211.5 ± 38.3 nm, whereas those from MCPyV-positive MCC varied between 
38.2 ± 4.3 and 227.0 ± 28.2 nm (Table 1). These results showed the size of the exosomes from MCC cell 
lines corresponds to the predicted size of exosomes. An exception was exosomes from the MCPyV-
negative cell line, UISO, for which the mean size of the first peak (9.9% of the UISO-derived exosomes) 
in ranged between 25.1 ± 2.6 nm in diameter. This is somewhat smaller than exosomes usually are 
considered to be [15, 38]. For the MCPyV-positive cell line MKL2, 57.7% of exosomes had a mean 
diameter of 177.4 ± 21.3 nm, which was slightly larger as reported in our previous work, but still in the 






Table 1. The exosomes size distribution was determined by photon correlation spectroscopy on 
submicron particle sizer model 370 and represented in intensity-weight distribution. 
 
The size of exosomes visualized by transmission electron microscopy was in agreement with the 
photon correlation spectroscopy measurement (Figure 1). The mean size range for exosomes from the 
MCPyV-negative MCC13 and MCPyV-positive MKL1 cell lines was observed between 30 and 180 nm 
in diameter.  
 
  
Figure 1. Characterizations of exosomes from supernatants of cell lines by transmission electron 
microscopy, x80 000 magnification. A section of purified exosomes produced using the negative contrast 
staining, the mean size range of observed exosomes was between 30 and 180 nm in diameter. Scale bar 
= 0.2 µm. 
Common canonical exosomal proteins can be used as markers to identify exosomes. Western blot 
analysis of the isolated exosomes demonstrated that they were positive for the exosomal marker CD63 
and negative for the cell contamination cis-Golgi marker, GM130 (Figure 2a) [40]. Total cell lysates were 
used as positive controls for the GM130 Golgi marker (Figure 2b).  
 
 
Figure 2. Characterizations of exosomal markers in exosome isolated from culture supernatants of MCC 
cell lines. (a) Evaluation of the negative protein GM130 (130 kDa), and the exosomal marker CD63 (50 
kDa) present in exosomes from MCPyV-negative and –positive cell lines by Western blotting. (b) 
Western blot analysis of GM130 protein in total cell lysates of MCC cell lines. GAPDH was used as 
loading control. 
2.2 Characterization of Exosomes from Healthy Donors and Patients Samples 
Exosomes isolated from serum/plasma samples of healthy donors (HD) and MCC patients (ME) 
were evaluated by several methods (Table 2). Exosomes of healthy human donors had been isolated 
from the donors’ pooled serum, prepared with quality and care. Each lot of exosomes was carefully 
characterized for particle size and concentration by NanoSightTM analysis, and expression of specific 
exosome protein markers CD9 and CD63 were validated by Western blot (not showed). On account of 
the small volumes of the patient samples two samples, ME18 and ME29 were chosen to study by Photon 
correlation spectroscopy and TEM as complementary methods to western blotting and qRT-PCR.  
Table 2. Characterization of exosomes purified from healthy donors (n = 4) and patients samples (n = 8) 
by several methods. 
 
The exosome size distribution was determined by photon correlation spectroscopy that showed 
the mean size of exosomes from HD in the range between 28.1 ± 1.8 and 168.2 ± 19.7 nm in diameter and 
the mean size of the exosomes from ME in the range between 26.4 ± 3.1 and 173.6 ± 8.9 nm in diameter 
(Table 3).  
Table 3. The size distribution of exosomes isolated from a healthy donor and MCC patient samples.  
 
 
Isolated exosomes were visualized by transmission electron microscopy (Figure 3). In spite of this 
small range, TEM confirmed the known size range of exosomes [15, 38]. The size distribution was in the 
range between 30 and 180 nm in diameter on HD and 25 and 200 nm in diameter on ME.  
 
   
Figure 3. TEM of exosomes from the serum of healthy donor HD1 and plasma of MCC patient ME18, x 
80 000 magnification. Scale bar = 0.2 µm.  
As shown in Figure 4, the analysis performed by Western blot on lysates of the vesicles using 
antibodies against the exosomal marker CD63 and negative control for GM130 confirmed that isolated 
vesicles are exosomes without any cellular contamination. These results confirmed that the vesicles 
isolated from the serum/plasma samples were exosomes based on their size and marker protein 
expression.      
 
Figure 4. Detection of exosomal marker CD63 protein in exosomes purified from serum samples of 
healthy donors (HD) and plasma samples of MCC patients (ME). Top panel: the exosome negative 
marker protein CM130 (130 kDa), and bottom panel: the exosomal marker CD63 (50 kDa).  
2.3. Exosomal miRNA Profiles Originated from Merkel Cell Carcinoma Cell Lines by Deep Sequencing  
To assess the exosomal miRNA profiles of Merkel cell carcinoma, deep sequencing of miRNA 
purified from exosomes originated from the MCPyV-negative MCC13 and MCC26, and the MCPyV-
positive MKL1 and MKL2 MCC cell lines was performed. Sequencing was performed with three 
independent exosomal RNA preparations for each cell lines. In total, 16 517 058 ± 5 527 592 reads for 
MCC13, 17 073 897 ± 1 603 976 reads for MCC26, 17 708 458 ± 5 192 408 reads for MKL1 and 30 364 588 
± 17 011 373 reads for MKL2, respectively were obtained. On average, 20.4 million reads obtained per 
sample. 
After mapping the data and counting to relevant entries in miRBase 20 the numbers of known 
miRNAs calculated (Figure 5). Identified miRNAs across each sample were for transcripts per million 
(TPM) >1: 299 ± 47 for MCC13 exosomes, 346 ± 53 for MCC26 exosomes, 364 ± 40 for MKL1 exosomes 
and 357 ± 17 for MKL2 exosomes. Identified miRNAs across each sample were for TPM >10: 152 ± 28 for 
MCC13 exosomes, 175 ± 30 for MCC26 exosomes, 181 ± 21 for MKL1 exosomes and 172 ± 9 for MKL2 
exosomes. In summary, the number of identified miRNAs with average TPM > 1 was 360 across all 
samples, and the number of identified miRNAs with average TPM > 10 was 198 across all samples. The 
reliability of the identified miRNAs increased with the number of identified fragments [41]. 
 
Figure 5. A number of identified known miRNA with the number of counts for each group of samples 
with average >1TPM and >10TPM. 
The miRNAs prediction found 439 predicted miRNAs in the dataset based on putative precursor 
hairpin structures and these included in the subsequent supervised differential expression analysis that 
gives the 519 differentially expressed miRNAs (Supplementary Material, Table S1). 
To illustrate the exosomal differentially expressed miRNA profiles of the four MCC cell lines 
unsupervised clustering of miRNAs and samples was performed. As shown in the dendrogram in 
Figure 6, MCPyV-negative and –positive cell lines were separated into two distinct clusters based on 
the exosomal miRNA profiles.  
 
Figure 6. Heat Map and unsupervised hierarchical clustering by samples and miRNAs. miRNAs and 
samples were clustered using Euclidean distance and complete linkage. Red and green colors indicate 
relatively high and low expression, respectively. Missing values are shown in gray. #1-3 refers to 
different replicates with independent exosomal RNA isolations. miRNAs selected for qRT-PCR 
validation are highlighted in red. 
Notably, several exosomal miRNAs were unique to specific MCC type. Supplementary Material, 
Table S2 includes the miRNAs that were ≥2-fold upregulated when comparing the miRNAome from 
exosomes derived from the virus-negative and virus-positive MCC cell lines. For MCC MCPyV-
negative and –positive cell lines, the miRNA existent pattern was not homogenous. Expression levels 
of miR-21-3p/5p, miR-22-3p/5p, miR-142-3p/5p, miR-199a-3p/5p, miR-199b-3p/5p, miR-409-3p/5p, miR-125b-
1-3p/5p and miR-3180-3p/5p in the exosomes originated from both MCPyV-negative MCC cell lines and 
expression levels of miR-532-3p/5p, miR-873-3p/5p and miR-6515-3p/5p in the exosomes originated from 
both MCPyV-positive MCC cell lines differed two-fold or more. 
2.4. Validation Analysis of miRNAs-Sequencing Data via qRT-PCR 
Differential expression of eight miRNAs was validated by qRT-PCR (Table 4). These miRNAs were 
also selected based on their previously described involvement in MCC [42-48] and other tumor types 
[49-54]. The five miRNAs upregulated in MCC MCPyV-negative cell lines compare to MCPyV-positive 
cell lines are miR-31-5p, miR-125b-1-3p, miR-143-3p, miR-222-3p and miR-584-5p. The three miRNAs 
upregulated in MCPyV-positive cell lines compare to MCPyV-negative cell lines are miR-141-3p, miR-
375 and miR-532-5p. miR-30a-5p, which was stably expressed across all samples as showed the NGS 
analysis, was used as an internal control for the validation study.  
Table 4. Validation of 8 selected microRNA from the exosomal microRNA sequencing result with qRT-
PCR method. miRNA sequencing evaluation shows ≥2-fold upregulation or down-regulation of 
microRNA in exosomes from MCC MCPyV-negative vs. MCPyV-positive cell lines. The qRT-PCR result, 
differences in miRNAs presence in exosomes from MCPyV-negative and –positive were assessed using 
the paired t-test. A P value of less than 0.05 considered statistically significant.   
 
The selected miRNAs were detected in all samples. This presence of miR-31-5p and miR-222-3p 
was further investigated in exosomes purified from serum 4 healthy donors and plasma 8 MCC patient. 
The qRT-PCR result confirmed that only exosomal miR-222-3p expression agrees with the NGS result. 
The miR-222-3p was upregulated in MCPyV-negative MCC cell lines (Figure 7a). A Mann-Whitney U 
test performed to determine whether there were differences in miR-222-3p expression level between 
samples. There was a statistically significant difference between the miR-222-3p levels in the exosome 
samples between the median of MCPyV-negative (1.659) and -positive MCC cell lines (0.008), U = 0, P = 
0.0022 (Figure 7b). The miR-222-3p was not statistically significant in exosome samples between the 
median of healthy donors (3.627) and patient (1.064), U = 7 (Figure 7b).  
 
 
   
Figure 7. Validation of exosomal miR-222-3p expression by qRT-PCR methods in MCC cell lines and 
serum and plasma samples of healthy individuals and MCC patients. a) The sequencing result (miRNA 
seq) marked Higher means that the miRNA is upregulated (≥2-fold) in exosomes from MCC MCPyV-
negative and down-regulated (≥2-fold) in exosomes from MCC MCPyV-positive. The qRT-PCR result, 
differences in miRNAs presence in exosomes from MCPyV-negative and –positive were assessed using 
the Mann-Whitney test. b) The relative miR-222-3p levels present in exosomes purified from MCC 
MCPyV-negative and –positive cell lines, serum from healthy donors (HD; n=4) and plasma from MCC 
patients (n=8). Differences in miR-222-3p presence in exosomes samples were assessed using the Mann-
Whitney test. The y-axes show arbitrary units representing the relative miRNA expression levels, error 
bars ± SD, **P-value < 0.005.  
 
To quote the exosomal miR-222-3p expression change in progress upon viral and cancer status in 
the circulatory system, healthy donors and patients’ samples quantified in relation to MCPyV-negative 
and –positive cell lines. There were no statistically significant differences between the fold changes of 
miR-222-3p in healthy donors (median = 477.7) and patients (median = 250.6) in relation to MCC 
MCPyV-positive cell line (not showed). There was the statistically significant difference between the 
fold change in miR-222-3p expression in exosome samples from healthy donors (1.626) and patients 
(0.241), respectively in relation to MCC MCPyV-negative cell line, U = 32.50, P = 0.0023. 
2.5. Prediction of putative miR-222-3p targets 
To understand the exosomal miR-222-3p influence in health and disease, miRNA’s target genes 
predicted using the ExoCarta, TargetScan, and miRTarBase [55-57]. As a result, 212 (ExoCarta), 245 
(TargetScan) and 394 (miRTarBase) potential target genes for miR-222-3p were identified 
(Supplementary Material, Table S3A: ExoCarta, S3B: TargetScan, and S3C: miRTarBase). The 
enrichment analyses were done by FunRich3.1.3 (Figure 8) [58]. Only 20 were shared by all three 
databases (Supplementary Material, Table S4).  
 
Figure 8. Venn-diagram of the overlap between the predicted target genes by ExoCarta, TargetScan, and 
miRTarBase, which shows 20 common targets of miR-222-3p (Supplementary Material, Table S4).  
These include sorting nexin-4 (SNX4), SUN domain-containing protein 2 (SUN2), stathmin 
(STMN1), 14-3-3 gamma (YWHAG), RNA-binding protein with serine-rich domain 1 (RNPS1), and 
importin subunit alpha-1 (KPNA2) that differentially expressed proteins on MCC cell lines (our 
unpublished data; Supplementary Material, Table S5). The 14-3-3 gamma protein was detected in 
extracellular vesicles originated from MCC cell lines [39]. Expression of SNX4, SUN2 and RNPS1 in 
MCC not been reported before. Besides these, target genes expressed in leukocytes (55.0%, P = 0.046), 
according to the enrichment analysis (Figure 9). 
 
Figure 9. Enrichment analysis of 20 common miR-222-3p predicted targets’ site of expression. The 
FunRich database as a background including only human genes and proteins, P-value < 0.05.  
Eleven of these twenty target genes such as sorting nexin-4 (SNX4); SUN domain-containing 
protein 2 (SUN2); stathmin (STMN1); 14-3-3 gamma (YWHAG); tumor protein p53 binding protein 2 
(TP53BP2); poly(A) binding protein interacting protein 2 (PAIP2); zinc finger FYVE-type containing 16 
(ZFYVE16); suppressor of cytokine signaling 3 (SOCS3); proline-rich nuclear receptor coactivator 2 
(PNRC2); dipeptidyl peptidase 8 (DPP8); and reversion inducing cysteine-rich protein with kazal motifs 
(RECK) expressed and were been reported before in leukocytes (Supplementary Material, Table S6) 
[59-68]. 
3. Discussion 
The present study has demonstrated the secretion of exosomes by Merkel cell carcinoma cell lines 
and the presence of exosomes in serum or plasma samples from healthy donors and MCC patients. The 
exosomes were an average 30 – 250 nm in diameter. The exosomal miRNAs contents from MCPyV-
negative and –positive MCC cell lines was investigated by high-throughput sequencing, showing 
differential expression in exosomes derived from virus-negative and virus-positive MCC cell lines. 
Results of this deep sequencing indicated that miR-222-3p was more abundant in exosomes generated 
by virus-negative MCC cells than in exosomes secreted by virus-positive MCC cell lines. RT-qPCR 
validation confirmed this finding. MiR-222-3p was also detected in exosomes purified from serum 
samples of healthy donors and plasma samples of MCC patients. The miR-222-3p presence at a higher 
level in exosomes in healthy condition than in pathophysiological condition. In the early studies, the 
plasma miR-222-3p identified as a strong intrinsic reference miRNA useful for the study of estrogen-
responsive miRNAs in pregnancy, and the other study concluded that there was no significant 
difference on the designation of miRNAs between plasma and plasma-derived exosomal, but the 
frequency was higher in plasma in healthy people [69-72].  
For the discussion, we focused on the role of exosomal miR-222-3p and their targets in cancer.  
MiR-222-3p has been detected in exosomes from cancer such as epithelial ovarian cancer, non-small 
cell lung cancer and breast cancer [52, 69, 70]. MiR-222-3p has described neither in tissues nor in cells 
from MCCs. [42-45]. These support selectivity of exosomal miRNAs, particularly miR-222-3p. 
The enrichment analysis showed 11 of predicted 20 common miR-222-3p targets expressed in 
leukocytes and six of them identified as differentially expressed proteins in MCC cell lines. The cancer 
cells and their exosomes likely interfere with the induction of an efficient immune response via several 
mechanisms inducing triggering T cell suppression mechanisms, attenuating NK cell cytotoxicity, and 
engaging pro-metastatic inflammatory processes and generating an immunosuppressive environment 
to escape from the immune system and eventually, treatment failure [73, 74]. 
Initially revealed that exosomal miR-222-3p derived from epithelial ovarian cancer induce 
polarization of tumor-associated macrophages [53]. Further, transferred miR-222-3p into subcellular 
sites in recipient cells induced repression of expression target genes [69]. One of the miR-222-3p target 
genes is the SOCS family, which is a major negative regulator of cytokine signaling that regulates 
development, subsets profiling and function of immune cells in carcinogenesis [75]. Moreover, the 
exosomal miR-222-3p demonstrated malignant characteristics and features as a regulator of gemcitabine 
resistance by targeting suppressor of cytokine signaling 3 (SOCS3) [69]. Furthermore, miR-222-3p was 
found to be enriched in exosomes from patients with hepatitis C virus (HCV) related immuno-
pathogenesis and miR-222-3p inhibited natural killer cells (NK) degranulation activity. Direct-acting 
antiviral (DAA) therapy markedly reduced the levels of exosomal miR-222-3p and restored NK function 
[76].  
There can be a distinct implication of exosomal miR-222-3p in the immunopathogenesis of MCC. 
The sorting nexin-4, inner nuclear membrane protein SUN2, and RNA binding protein with serine-rich 
domain 1 were never mentioned to be associated with MCCs, but a stathmin 1 associated with MCPyV 
ST antigen, which mediates microtubule destabilization to promote cell motility and migration in MCCs 
[78, 79]. The karyopherin alpha 2 induced expression found in MCCs and it is essential for ribosomal 
RNA (rRNA) transcription and protein synthesis in proliferating keratinocytes [80]. Interestingly, MCC 
cell lines' exosomes content 14-3-3 protein gamma (YWHAG) [39].  14-3-3 protein gamma is one of the 
oncogenic Wnt pathway’s activation factor, and an additional factor of PI3/Akt/beta-catenin signaling 
on cell proliferation [81, 82]. Recently, Chu and colleagues showed that level of miR-222 was 
significantly lower in osteosarcoma tumor tissue samples than that in the group of samples from healthy 
individuals. MiR-222 over-expression decreased cell proliferation and invasion in osteosarcoma [83]. 
Moreover, reduced miR-222 promoted YWHAG expression and up-regulation of YWHAG restored the 
inhibiting effect of miR-222 mimics [83]. Wei and colleagues’ study of exosomal miR-222-3p concluded 
that a higher level of these exosomal miRNAs in serum from non-small cell lung cancer (NSCLC) 
patients usually predicted a worse prognosis [69]. Thus, the exosomal miR-222-3p and its targets may 
play a pleiotropic role in MCC tumorigenesis and drug resistance. 
A current limitation of this project is an exclusive pilot study of exosomes and exosomal miRNAs 
in plasma samples from MCC patient and the comprehensive exosomal miRNA analysis in MCC cell 
lines.  
In conclusion, our results showed that the presence of exosomal miR-222-3p in exosomes derived 
from MCC cell lines, healthy donors and MCC patients. There was a statistically significant higher level 
of miR-222-3p in the exosome samples from MCPyV-negative compared with virus-positive MCC cell 
lines, suggesting higher levels of miR-222-3p in MCPyV-negative than MCPyV-positive MCC tumor. 
The miR-222-3p usefulness as a biomarker needs to be further explored and its role in MCC remains 
elusive. The target genes’ scanning indicates that the exosomal miR-222-3p play pleiotropic role 
dependent on recipient cells in health and disease. 
4. Materials and Methods  
4.1. Samples 
4.1.1. Cell Culture 
The human Merkel cell polyomavirus-negative cell lines MCC13, MCC26 and UISO, and 
polyomavirus-positive Merkel cell carcinoma cell lines MKL-1, MKL-2 were a kind gift from Dr. B. 
Akgül (Institut für Virologie Uniklinik Köln, Köln, Germany) and WaGa. All cell lines were kept in 
culture medium RPMI-1640 (Sigma-Aldrich, Oslo, Norge) supplemented with 10% exosome depleted 
fetal bovine serum (exosome-depleted FBS, SBI, CA, USA). All cell types were incubated in a 5% CO2 
humidified incubator at 37⁰C. FBS-associated-exosomes were stripped and were removed by dilution of 
FBS in RMPI-1640. Then, a cell suspension was collected and centrifuged for 5 minutes at 200 x g to 
remove whole cells. The collected supernatants stored in aliquots at -80 ⁰C.   
4.1.2. Donor and Clinical Samples 
Purified Exosomes from serum from healthy donors were purchased from Sanbio B.V. (Uden, The 
Netherlands).  
Whole blood samples from 8 MCC patients were collected in heparinized tubes at Karolinska 
University Hospital. The blood samples were centrifuged to separate plasma at 10,000 rpm for 10 min 
and store at -80 °C until use. The study was approved by the Ethics Committee of Karolinska Institutet. 
All patients provided informed consent in written form. 
4.2. Extracellular Vesicles Isolation and Purification  
The supernatants were thawed and centrifuged (Allegra® X-15R, Beckman Coulter Inc., Palo, CA, 
USA) for 15 minutes at 3000 x g to remove dead cells. Then, the supernatants were sterile-filtered using 
a 0.2 µm filter (Pall Corporation, Ann Arbor, MI, USA). Extracellular vesicles were isolated by 
ExoQuick-TCTM Exosome Precipitation Solution (SBI, CA, USA) according to the manufacturer's 
instruction. Briefly, the appropriate volume of ExoQuick-TC Exosome Precipitation Solution was added 
to the supernatant. The mixture was incubated for 12 hours at 4⁰C and centrifuged (Beckman Coulter 
Inc.) twice at 1500 x g for 30 and 5 minutes at room temperature. The supernatant was removed without 
disturbing the precipitated extracellular vesicles. The exosomes were purified by ExoQuick® ULTRA 
EV Isolation kit (SBI). The pellet containing the exosomes was re-suspended in 200 µl buffer A. The 
purification column was washed two times and 100 µl of buffer B was applied on top of the resin to 
prep it for sample loading. The re-suspended extracellular vesicles were added to the column and mixed 
at room temperature on a rotating shaker for 5 minutes. To obtain exosomes, the column was transferred 
to 2 ml Eppendorf tube and centrifuged at 1000 x g for 30 seconds.  
The serum samples were thawed and centrifuged (Allegra® X-15R, Beckman Coulter Inc.) at 12000 
x g for 10 minutes. The supernatant was transferred to a new tube. Then, extracellular vesicles were 
isolated by ExoQuick® ULTRA EV Isolation kit for serum and plasma (SBI) according to the 
manufacturer's instruction. Briefly, the appropriate volume of ExoQuick-TC Exosome Precipitation 
Solution was added to the supernatant. The mixture was incubated for 30 minutes at four ⁰C and 
centrifuged at 3000 x g for 10 minutes at room temperature. The supernatant was removed, and the 
precipitated extracellular vesicles were purified by ExoQuick® ULTRA EV Isolation kit (SBI) as 
mentioned above. 
4.3. Electron Microscopy Imaging 
For negative staining, 5 µl drops of exosomes (in PBS) were adsorbed onto 75 lines/inch Hexagonal 
Mesh copper/0.7% formvar (Sigma-Aldrich)-coated grids (Electron Microscopy Sciences, Chemi-Teknik 
AS, Oslo, Norge) for 5 min, washed by dabbing the grid onto four drops of double distilled water, and 
stained with 0.3% uranyl acetate (Sigma-Aldrich) and 2% methylcellulose (Sigma-Aldrich) for 2 
minutes. The grid was examined at 80 kV with a JEOL JEM-1010 (JEOL Ltd, Peabody, MA, USA), and 
images were acquired with a digital camera Morada (Olympus Soft Imaging System, Münster, 
Germany). 
4.4. Photon Correlation Spectroscopy   
The particle size distributions of extracellular vesicles were determined by photon correlation 
spectroscopy (Submicron particle sizer model 370, Nicomp, Santa Barbara, CA, USA). To avoid 
interference from dust particles, the test tubes to be used for the determination were filled with distilled 
water and sonicated for 10 min in an ultrasonic bath, then rinsed with filtered water (using 0.2 µm filter) 
prior to the experiments. All formulations were prepared in a laminar airflow bench, and analyses run 
in vesicle mode and the intensity-weight distribution at 23-24 °C [84]. Three parallels were determined 
(run time at least 25 min) for each sample measurement. 
4.5. RNA Isolation 
Total exosomal RNAs were extracted using the SeraMir Exosome RNA Purification kit (SBI), 
according to the manufacturer’s instruction. Briefly, 350 µl of lysis buffer was added to EVs pellet and 
vortexed for 15 seconds. The re-suspended exosomes were then placed at RT for 5 minutes to allow 
complete lysis. Then 200 µl of 100% ethanol was added, and the solution was vortexed for 10 seconds. 
The lysed exosomes were then transferred to a spin column and centrifuged at 13000 rpm for 1 minute. 
The column was washed twice by adding 400 µl of wash buffer to the column followed by centrifugation 
for 1 min at 13000 rpm. The flow-through was discarded, and the column was centrifuged at 13000 rpm 
for 2 minutes to ensure it was completely dry. The total RNAs were eluted in 30 µl elution buffer. The 
column was centrifuged at 2000 rpm for 2 min to allow the buffer to spread in the column and there 
after for 1 min at 13000 rpm to elute exosomal RNA.      
4.6. microRNA Sequencing 
The microRNA sequencing and analysis were ordered as a commercial service from Exiqon A/S 
(Vedbæk, Denmark). The library preparation and Next Generation sequencing were conducted at 
Exiqon. Briefly, the library preparation was done using the NEBNext® Small RNA Library preparation 
kit (New England Biolabs, Ipswich, MA, USA). A total of 100 ng of total RNA was converted into 
microRNA NGS libraries. Adapters were ligated to the RNA. Then RNA was converted to cDNA. The 
cDNA was amplified using PCR (15 cycles), and during the PCR indices were added. After PCR the 
samples were purified. Library preparation QC was performed using Bioanalyzer 2100 (Agilent, Santa 
Clara, CA, USA). Based on the quality of the inserts and the concentration measurements, the libraries 
were pooled in equimolar ratios. The pool was then size selected using the LabChipXT (PerkinElmer, 
Denmark) aiming to select the fraction with the size corresponding to microRNA libraries (~145 nt). The 
library pools were quantified using the qPCR KAPA Library Quantification Kit (KAPA Biosystems). 
The library pool was then sequenced on a NextSeq 500 sequencing instrument according to the 
manufacturer’s instructions. Raw data was de-multiplexed, and FASTQ files for each sample were 
generated using the bcl2fastq software (Illumina Inc.). FASTQ data were checked using the FASTQC 
tool (Babraham Bioinformatics, London, UK). 
An average of 20.4 million reads was obtained per samples. The numbers of known miRs were 
calculated after mapping the data and counting to relevant entries in miRBase 20. The reliability of the 
identified miRNAs increased with the number of identified fragments. Samples were grouped as per 
their type identifiers, and quantification of miRNAs abundance was done. 
For clustering analysis, miRNAs counts were normalized by trimmed mean method (TMM) and 
the normalized expression value was log transformed and clustered based on Euclidean distance and 
complete linkage using the Cluster 3.0 software 
(http://bonsai.hgc.jp/~mdehoon/software/cluster/software.htm) and visualized with Java TreeView 
version 1.1.6 (http://jtreeview.sourceforge.net/). 
4.7. NuPage Gel Electrophoresis and Western Blotting 
Exosomes were purified, harvested in RIPA Lysis and Extraction Buffer containing HaltTM Protease 
(Thermo Fisher Scientific Inc.). The exosomal protein concentration was determined by the Direct 
Detection method (Direct Detect Spectrometer, Merck Life Science AS, Oslo, Norway) as described 
previously [85]. Equal amounts of protein (30 µg) were loaded on a 4-12% NuPage Novex gel (Life 
Technologies, Oslo, Norway) and separated by electrophoreses. Then proteins from exosomes were 
transferred to an Immobilon-FL PVDF membrane. The blotting membrane was blocked with Odyssey 
Blocking Buffer (BB, Li-Cor Biosciences GmbH, Bad Homburg, Germany), mouse CD63 (1:1000, Abcam) 
and rabbit GM130 (1:10000, Abcam) followed by incubation with anti-mouse Alexa 680 (1:5000, 
Molecular Probes) and anti-rabbit IRD800 (1:5000, Rockland) IgG secondary antibody. The proteins 
were detected using an Odyssey scanner (Li-COR Inc., USA).  
Cultured cells were washed briefly with phosphate-buffer saline (PBS, Biochrom GmbH) and 
harvested in RIPA Lysis and Extraction Buffer containing HaltTM Protease and Phosphatase Inhibitor 
Cocktail (Thermo Fisher Scientific Inc.). Following sonication, the protein concentration was determined 
using a Protein Quantification Assay (MACHEREY-NAGEL GmbH & Co. KG, Düren, Germany). The 
protein lysates (30 µg) were supplemented with NuPAGE® LDS Sample Buffer (4X) (Thermo Fisher 
Scientific Inc.) as well as 100mM DTT (Sigma-Aldrich Norway AS) and incubated for 10min at 70°C. 
Equal amounts of protein were separated on NuPAGE™ Novex™ 4-12% Bis-Tris Protein Gels (Thermo 
Fisher Scientific Inc.) and transferred onto a 0.45μm PVDF Membrane (Merck Life Science AS, Oslo, 
Norway) according to the XCell SureLock Mini-Cell technical guide (Thermo Fisher Scientific Inc.). The 
membranes were blocked in TBS-T (Tris-buffered saline (TBS) with 0.1% Tween-20; Sigma-Aldrich 
Norway AS) containing 5% (w/v) skimmed milk powder. Incubation with primary antibodies Anti-
GM130 (1:2000, Abcam) and Anti-GAPDH (1:4000, Santa Cruz Biotechnology) was performed overnight 
at 4°C according to antibody supplier recommendation in either blocking buffer or 5% BSA 
(AppliChem, Darmstadt, Germany) in TBS-T. Following three washes in TBS-T, the membranes were 
incubated in the appropriate secondary antibody solutions Goat Anti-Rabbit IgG H&L (HPR, 1:50000, 
Abcam) and Rabbit Anti-Mouse IgG H&L (HPR, 1:20000, Abcam) for 1h at room temperature. After 
four washes, detection and visualization were performed using SuperSignal™ West Pico 
Chemiluminescent Substrate (Thermo Fisher Scientific Inc.) and the ImageQuant LAS 4000 imager (GE 
Healthcare, Oslo, Norway). MagicMark™ XP Western Protein Standard (Thermo Fisher Scientific Inc.) 
was used to estimate the molecular mass of the detected proteins.  
4.8. Quantitative RT-PCR  
For quantification of miR levels, total exosomal RNA was extracted using the SeraMir Exosome 
RNA Purification kit (SBI), according to the manufacturer’s instruction. RNA concentrations were 
determined on a CLARIOstar (BMG Labtech Inc., Cary, NC, USA). The cDNA synthesis was performed 
using the High Capacity cDNA Reverse Transcriptase kit (Applied Biosystems, Life Technologies, 
USA), according to the manufacturer’s instructions for TaqMan Small RNA Assays. MiRNAs cDNAs 
were quantified by qRT-PCR using LightCycler® 96(Roche Diagnostics, Indianapolis, IN, USA) with 
the TaqMan Universal Master Mix II, no UNG (Applied Biosystems) and TaqMan Fast Advanced 
Master Mix (Applied Biosystems). The miR-specific primers and probes were obtained from Thermo 
Fisher Scientific (Waltham, MA, USA) listed in Table 5. To calculate the relative expression levels of 
target miRNAs, the delta-Cq and the delta-delta-Cq algorithm method was utilized [86]. MiR-30a-5p 
was stably expressed across all samples and was therefore used as an internal control for normalization. 
Table 5. The miR-specific primers and probes for two steps qRT-PCR. 
 
4.8. Prediction of Target Genes for miR-222-3p  
The miR-222-3p target genes were predicted using the ExoCarta, TargetScan, and miRTarBase 
databases [55-57]. Targets genes were analyzed for enrichment by FunRich3.1.3 (www.funrich.org) 
open-access tool. The enrichment analysis of the site of expression was performed and graphs 
constructed by the FunRich3.1.3 [58]. 
4.9. Data Analysis 
The distribution of observed data was determined using descriptive statistics. For the qRT-PCR, 
the average Cq for each triplicate from the qRT-PCR was calculated. The relative quantification was 
used to compare the presence of exosomal miR-222-3p in MCPyV-negative, MCPyV-positive, healthy 
donors and patients samples normalized with miR-30a-5p as an internal control. The fold change was 
calculated by the delta-delta-Cq method with miR-30a-5p as an internal control. All comparison was 
performed using the Mann-Whitney U test. All statistical analyses were conducted and graphs 
constructed by the Prism 8 (GraphPad Software Inc., San Diego, CA, USA). Data are presented in 
median and a P value less than 0.05 were considered statistically significant (*P < 0.05, **P < 0.005). 
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Abbreviations 
CD63 Cluster of differentiation 63 
GM130 Anti-GM130 antibody 
HCV Hepatitis C virus 
KPNA2 Importin subunit alpha-1 
NK Natural killer 
PD-1 Program death-1 
RNPS1 RNA-binding protein with serine-rich domain 1 
SNX2 Sorting nexin-2 
SOCS Suppressor of cytokine signaling 
STMN1 Stathmin 1 
SUN2 SUN domain-containing protein 2 
TMM The trimmed mean of M-value normalization method 
TPM Tags per million 
YWHAG Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein gamma  
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Abstract   
Proteomics have become an important tool in discovery and understanding pathological 
processes at cellular level. Comparing the proteome of normal cells with diseased (malignant 
and other pathological conditions) or pathogen-infected cells allows identification of proteins 
and processes involved in the disease, and recognition of possible biomarkers and targets for 
treatment. Merkel cell carcinoma (MCC) is an aggressive type of cutaneous cancer that affects 
mostly elderly people. Approximately 80% of the tumors are caused by Merkel cell 
polyomavirus (MCPyV), while the remaining are caused by UV-induced mutations in the DNA 
of the cell. To understand the underlying mechanisms of virus-independent and virus-dependent 
MCC, we compared the proteome of MCPyV-negative (MCC13, MCC26, and USIO) and 
MCPyV-positive (MKL-1, MKL-2, MS-1, and WaGa) MCC cell lines. In total 4898 proteins 
were identified, of which 3312 were differentially expressed between the virus-negative and 
virus-positive cell lines. The viral oncoproteins large T- and small t-antigens were detected in 
the MCPyV-positive cells, but also in exosomes derived from these cells. Our proteomic data 
may identify unique biomarkers for MCPyV-negative and –positive MCCs and may allow the 
design of specific therapeutic strategies against the two types of MCC with different origin. 
Moreover, our results suggest that exosomal transmission of MCPyV oncoproteins to recipient 
cells in the tumor microenvironment contributes to tumorigenesis. 
 






Merkel cell carcinoma (MCC) is a rare, but aggressive neuroendocrine form of skin cancer with 
poor prognosis. About 20% of all MCC cases are associated with chronic UV light exposure, 
while the remaining 80% caused by Merkel cell polyomavirus [1, 2]. A hallmark for MCPyV-
positive MCC is the integration of the viral genome [3]. This viral genome encodes the 
regulatory proteins large T antigen (LT), small T antigen (ST), 57 KT and alternative to Large 
T Open reading frame (ALTO)  [4]. While the function of the latter two proteins remains 
unknown, LT and ST have oncogenic potentials in cell culture and animal models [5-14]. 
Another characteristic of MCPyV-positive MCC is the expression of a C-terminal truncated LT 
[3]. Despite the oncogenic properties of LT and ST, it is unclear if the presence or absence of 
integrated MCPyV alters the course or/and outcome of MCC [13, 15]. To understand the 
underlying mechanisms by which MCPyV contributes to MCC tumorigenesis and to identify 
potential biomarkers and therapeutic targets, we compared for the first time the proteomes of 
MCPyV-negative and -positive MCC cell lines. We also analyzed our previously published 
proteomic data of extracellular vesicles derived from MCC cell lines (PXD004198; [16]) for 
the presence of viral proteins. We found that more than 3000 proteins differentially expressed 
between virus-negative and virus-positive MCC cell lines and that MCPyV may use exosomes 
to transmit its oncoproteins LT and ST to recipient cells in the tumor microenvironment.  
 
Results and Discussion 
Proteins were isolated from the MCPyV-negative MCC13, MCC26, and UISO cell lines (group 
1) and the virus-positive MKL-1, MKL-2, MS-1, and WaGa cell lines (group 2) by differential 
centrifugation and gel separation and subjected to mass spectrometry-based proteomics. All 
experiments run in triplicate. In total, 4898 proteins (Supplementary Table 1) identified, of 
which 3312 (Supplementary Table 2) showed differential expression between the two groups. 
We performed hierarchical clustering to determine groups of samples with similar global 
protein expression profiles (Figure 1). The MCPyV-negative cell line samples formed a group 
divergent from the MCPyV-positive cell line, indicating that these cell lines are distinct from 





Figure 1. The dendrogram shows the hierarchical relationship between the samples with similar 
global protein expression profiles. The MCPyV-negative cell lines are MCC13, MCC26 and 
UISO, and the MCPyV-positive MCC cell lines are MKL-1, MKL-2, MS-1, and WaGa. All 





The differences in protein expression can also be visualized in a principal components analysis 
(PCA) projection and with Volcano plot (Figure 2A and 2B). Again, these analyses indicate 
that the two groups of cells are distinct from each other. 
 
 
Figure 2. Two groups of divergent samples are the MCPyV-negative and -positive cell lines, 
which depicted A. Principal components (PCA) projection. B. Volcano plot. 
Distinctions between the two groups of cells are expected by the PCA and Volcano plot because 
of morphological and genotypic differences between the cell lines and their grow conditions 
[17-20]. Comparing virus-negative and –positive cell lines identified proteins with significantly 
increased and decreased expression (Supplementary Table 2). To quantify the overall 
similarity in protein expression, Spearman’s rank correlation coefficients between individual 
expressions profiles of MCC cell lines were computed (Supplementary Table 3). A strong, 
positive correlation (r = 0.70, n = 9, P = 0.0433) in protein expression between MCPyV-





Figure 3. Spearman’s correlation showing the relationship between protein expression in 
MCPyV-negative and –positive MCC cell lines (r =0.70, n = 9, P = 0.0433). Each dot represents 
one MCC cell line. The closer r is to ±1 the stronger the monotonic relationship. The strength 
of the correlation: r = 0.00-0.19 is "very weak"; r = 0.20-0.39 is "weak"; r = 0.40-0.59 is 
"moderate"; r = 0.60-0.79 is "strong"; and r = 0.80-1.00 is "very strong". 
 
The fifty most increased and decreased proteins in MCC cell lines are given in Table 1 and 
Table 2. The expression level for these proteins in other tumors compared to healthy tissue is 
included.  
Table 1. Fifty proteins with most increased expression in virus-negative MCC cell lines 
compared to virus-positive MCC cell lines and their expression in other tumors. The number in 
parenthesis refers to the row number in Supplementary Table 2. 
Protein name abbreviation function expression in cancer 
and in MCC cell 
line 
reference 
Annexin A2 ANXA2 (1071) cellular growth, cell 
motility, exocytosis, 
signal transduction,  
Increased/Increased 
in MCPyV-negative 
MCC cell lines  
[21] 
 
Annexin A1 ANXA1 (1035) anti-inflammatory 
activity, innate immune 
response, regulates 


















MCC cell lines 
[23] 
Transgelin TAGLN (1844) architecture cytoskeleton  Increased/ Expressed 
poor 
[24] 
Major vault protein MVP (2040) nucleo-cytoplasmic 





MCC cell lines 
[25] 
Myoferlin MYOF (3052) membrane regeneration 








CAPN2 (1220) Protease that cleaves 
substrates involved in 
cytoskeletal remodeling 
and signal transduction 
Increased/Increased 
in MCPyV-negative 
MCC cell lines 
[27] 




Participates in the 
connection between 
extracellular matrix 
adhesion sites and the 
actin cytoskeleton, 
architecture cytoskeleton  
Increased/Increased 
in MCPyV-negative 
MCC cell lines 
[28] 
Caldesmon 1 CALD1 (459) Stabilizes actin, role in 










MCC cell lines 
[30] 
Perilipin-3 (TIP47) PLIN3 (853) Involved in endosome-
to-Golgi transport, the 




MCC cell lines 
[31, 32] 
Plectin PLEC (2074) architecture 
cytoskeleton, scaffold 










Serpin B6 (Hsp47) SERPINB6 
(1408) 
prevents cellular damage 















MCC cell lines 
[35] 
Serpin H1 SERPINH1 
(1582) 
Collagen biosynthesis Increased/ Increased 
in MCPyV-negative 
MCC cell lines 
[36] 
Adenylyl cyclase-
associated protein 2 
CAP2 (1455) Actin remodeling Increased/ Increased 
in MCPyV-negative 
MCC cell lines 
[37] 
PDZ and LIM domain 
protein 7 
PDLIM7 (2963) Gene transcription, a 
scaffold protein, 




MCC cell lines 
[38] 




MCC cell lines 
[39] 
A-kinase anchor protein 
12 





MCC cell lines 
[40] 
Actin, aortic smooth 
muscle 
ACTA2 (1754) Cell motility, 
cytoskeleton structure 







RRBP1 (3074) the interaction between 






MCC cell lines 
[42] 














UGDH (856) biosynthesis of 
glycosaminoglycans, 
which play roles in signal 




MCC cell lines 
[44] 
vimentin VIM (1092) Cytoskeleton compound 
responsible for cell shape 






MCC cell lines 
[45] 
[46-49] 




MCC cell lines 
[50] 
Lipoma-preferred partner LPP (2590) cell-cell adhesion and 





MCC cell lines 
[51] 
Glycogen phosphorylase, 
liver form; -1,4 glucan 
phosphorylase 
PYGL (1063) carbohydrate metabolism Increased/ Increased 
in MCPyV-negative 
MCC cell lines  
[52] 
-parvin PARVA (627) reorganization of the 
actin cytoskeleton, cell 




MCC cell lines 
[53] 




MCC cell lines 
[54] 
Caveolae Associated 
Protein 1 or Polymerase I 












FKBP10 (2605) Protein folding Increased/ Increased 
in MCPyV-negative 
MCC cell lines 
[56] 
Utrophin UTRN (1519) anchoring the 












ILK (114) regulation integrin-
mediated signal 
transduction, essential in 




MCC cell lines 
[57] 
Integrin -2 ITGA2 (1217) organization of 
extracellular matrix, 




MCC cell lines 
[58] 
LIM and calponin 
homology domains-
containing protein 1 
LIMCH1 (3190) Architecture 
cytoskeleton, a negative 





MCC cell lines 
 
Gamma-interferon-
inducible protein 16 
IFI16 (2147) Transcriptional 
regulation, modulates 





























PLOD3 (851) Post translational 
modifications necessary 






MCC cell lines 
[62] 









MCC cell lines 
[64] 
Vinculin VCL (1230) Architecture 
cytoskeleton, cell-matrix 
adhesion and cell-cell 
Increased/ Increased 
in MCPyV-negative 







Integrin alpha-V; Integrin 
alpha-V heavy chain; 
Integrin alpha-V light 
chain 












MCC cell lines 
[67] 










PFKM (237) glycolysis Not investigated/ 
Increased in 
MCPyV-negative 










MCC cell lines 
[70] 
Flavine reductase 
(NADPH) or Biliverdin 
Reductase B 
BLVRB (1358) cellular redox regulator 






MCC cell lines 
[71, 72] 
Ephrin type-A receptor 2 EPHA2 (1348) Signaling pathways 
involved in migration, 
integrin-mediated 
adhesion, proliferation 








NNMT (1458) N-methylation of 











Table 2. Fifty proteins with most increased expression in MCPyV-positive MCC cells 
compared to virus-negative MCC cells and their expression in other tumors. The number in 
parenthesis refers to the row number in Supplementary Table 2. 
Protein name abbreviation function expression in cancers reference 
Nesprin-2 SYNE2 (2534) Cytoskeletal 
organization and 
cell motility  




Carboxypeptidase E CPE (1208) production of 
neuropeptides 
and role in the 
secretory 
pathway 












CKMT1A (1159) catalyzes 
phosphorylation 
of creatine  


























binding protein 1 
CRABP1 (1352) Binding and 
transport 
retinoid acid 


















related protein 5 




positive MCC cell lines 
 
Spectrin beta chain, 
non-erythrocytic 2 
















Kinesin heavy chain 
isoform 5C 
KIF5C (840) intracellular 
transport 













































INSM1 (1834) The transcription 
factor, a 
regulator of cell 
differentiation 
and cell cycle 








regulatory protein 1 
ESRP1 (2275) mRNA splicing 
factor 






















Dachshund homolog 1 DACH1 (3131) Transcription 
factor, regulation 
cell proliferation 

















subunit  O1 
GNAO1 (1104) signal 
transduction 






























Coenzyme Q Protein 







function in the 
respiratory chain  
Not investigated/ 
Increased in MCPyV-
positive MCC cell lines 
 












































































METTL7A (580) Tumor 
suppressor, 
recruit cellular 
proteins for lipid 
droplet 
formation 







Zinc finger protein 
385A 
ZNF385A (2681) Transcription 
factor and RNA-
binding protein 
that affects the 
localization and 
the translation of 




positive MCC cell lines 
 
Ribosomal protein S6 
kinase -1 
(RSK1/MAPKAPK1) 









Heat shock-related 70 
kDa protein 2 
HSPA2 (1655) Molecular 
chaperone 
implicated, e.g. 
in the protection 
of the proteome 
from stress, 
correct folding, 






















lactate and other 
precursors 
derived from the 
citric acid cycle 






















like anchor protein 















V-type proton ATPase 
subunit isoform 1 
ATP6V0A1 (2589) assembly and 



















VPS13A (2693) Trans Golgi 
transport 






associated protein 1 







positive MCC cell lines 
 
Ribosomal protein S6 
kinase alpha-5 





and activation of 




















ISOC1 (2613) unknown Not investigated/ 
Increased in MCPyV-
positive MCC cell lines 
 
 
The proteomic analysis shows that MCPyV-positive MCC cell lines have a high number of 
unique peptides for the medium molecular weight neurofilament protein (NF-M) and neuronal 
intermediate filament proteins, -internexin, than the MCPyV-negative cell lines, and that the 
latter are negative for the high molecular weight neurofilament protein (FN-H). Peripherin was 
not detected in MCC13, MCC26, and WaGa, but was abundant in MKL2. A high number of 
neuronal intermediate filament protein, nestin, found in MCC13 and UISO. The results 
underscore the neuroendocrine origin of the cell lines [111].  
Two major clusters with a size of 1510 (Supplementary Table 4) and 1170 (Supplementary 
Table 5) proteins differentially expressed between MCPyV-negative and –positive MCC cell 
lines included 63 and 83 components of cellular compartments and biological pathways that 
up-regulated in MCPyV-positive and -negative MCC cell lines, respectively. The proteomic 
profile also revealed that MCPyV-positive MCC cell line cells had up-regulated expression of 
proteins involved in cellular pathways among epigenetic regulation of gene expression (P = 
5.83E-07), histone modification (P = 2.82E-04), gene silencing (P = 6.45E-04), and RNA 
polymerase II-mediated transcription (P = 5.15E-06). In addition, data from virus-positive cells 
revealed increased expression of proteins involved in DNA replication (P = 1.89E-12), DNA 
recombination (P = 8.15E-09), DNA modification (P = 1.11E-03), DNA-dependent 
transcription termination (P = 1.73E-04), DNA repair (P = 3.52E-07), and DNA ligation (P = 
8.94E-03). The increased demand for DNA synthesis requires enhanced metabolic activity of 
one-carbon (P = 3.01E-03), nucleobase-containing (P = 1.11E-21), cellular nitrogen compound 
(P = 7.08E-22), and nitrogen compounds (P = 1.43E-20). Moreover, cancer cell rewires their 
metabolic processes [112, 113]. E.g., cancer cells enhance "aerobic" glycolysis, known as the 
Warburg effect, to support rapid cell proliferation [114]. This Warburg effect seems to apply 
for MCPyV-positive MCC cell lines because they had upregulated expression of proteins 




complex (P = 1.87E-05). An active transforming cell phenotype requires high energy. Lactate 
dehydrogenase B (LDHB) catalyzes the reversible conversion of lactate to pyruvate, and NAD 
to NADH, in the glycolytic pathway. With NADH accumulation, decreased mitochondrial 
oxidative phosphorylation occurs [115]. Cells that have a greater impairment of oxidative 
phosphorylation and high NADH production become more aggressive and metastatic [116], 
which is typical for the MCPyV-positive MCC. In contrast, the MCPyV-negative MCC cell 
lines profiles indicate that cells’ metabolism switched to amine (P = 1.57E-03), polysaccharide 
(P = 8.61E-03) and carbohydrate (P = 4.20E-03) metabolic processes for cell growth (P = 
1.05E-02), proliferation (P = 4.99E-03) and differentiation (P = 1.64E-03). Polyamines play a 
pleiotropic role, from modulating nucleic acid conformation to promoting cellular proliferation 
and signaling (signal transduction, P = 6.73E-06) [117]. Proteins implicated in cell motility (P 
= 4.04E-04), establishment or maintenance of cell polarity (P = 5.47E-03), cell surface (P = 
4.05E-09), locomotion (P = 9.57E-05), and cellular membrane organization (P = 7.49E-04) 
were upregulated in MCPyV-negative MCC cells, indicating high invasiveness and metastasis 
of these cells. Differential expression of proteins involved in post-translational modification 
such as protein glycosylation (P = 1.04E-05), peptidyl-amino acid modification (P = 2.05E-
04), protein folding (P = 4.86E-03), and protein modification process regulation (P = 5.24E-
03) was observed. Upregulation of protein glycosylation of surface molecules showed a key 
feature of cancer cells, which use the endoplasmic reticulum (ER, P =1.35E-08)/Golgi 
apparatus (P = 1.28E-03) to add carbohydrates to their cumulative glycoproteins [118]. Thus, 
data indicates that the MCPyV-negative MCC cells, compared to virus-positive MCC cell lines, 
have a lower expression of proteins that participate in DNA, RNA and protein synthesis and 
regulation, but have upregulated expression of proteins engaged in post-translational 
modification. Hence, cancer progression and high cell proliferation may lead to transcription-
associated mutation (TAM) and transcription-associated recombination (TAR) that gave a rise 
a high mutational burden of MCPyV-negative MCC.  
Other proteins that were expressed at higher levels in virus-negative cell lines compared to 
virus–positive cell lines included proteins involved in endocytosis (P = 4.06E-06), exocytosis 
(P = 8.44E-03), intra- and extracellular vesicle-mediated-transport (P = 4.93E-10), Golgi 
vesicles (P = 1.25E-05), protein sorting (P = 3.66E-03). An exception was valosin-containing 
protein (VCP), aconitase 1 (ACO1) and argininosuccinate synthase 1 (ASS1), which were only 
detected in extracellular vesicles from MCPyV-positive cell lines. VCP is a membrane ATPase 




membranes [119, 120]. ACO1 is the moonlighting protein based on its ability to perform 
mechanistically distinct functions. One of the ACO1’s ability is to bind glucose-regulated 
protein 94 kDa (Grp94), which is the ER-localized isoform of heat shock protein 90 (Hsp90). 
Hsp90 is responsible for trafficking and maturation of Toll-like receptors, immunoglobulins, 
and integrins [121]. ASS1 is a key enzyme in the citrulline-nitric oxide (NO) cycle, which can 
be upregulated by nitrogen efflux at Kaposi’s sarcoma-associated herpesvirus (KSHV) 
infection and acid-induced downregulation contributes to the maintenance of intracellular pH 
in cancer [122, 123]. Evolutionary, exosomes maintain cellular homeostasis by carrying cellular 
remains from the misfolded proteins loaded on the ER through the Golgi and subsequently 
removing these waste products by exocytosis to prevent genotoxic conditions [124].  
To validate some of our results, we compared our proteomic data with proteins that had been 
previously reported to be differentially expressed in these virus-negative and virus-positive 
cells [125, 126].  Guastafierro and colleagues had used immunohistochemistry (IHC) to 
investigate the expression of the positive MCC markers cytokeratin 1 (CK1), CK8, CK18 and 
CK20, and neuron-specific enolase (NSE), chromogranin A and synaptophysin, and the 
negative markers CK7, leukocyte common antigen (LCA) and thyroid transcription factor 1 
(TTF-1) in the MCC13, MCC26, and UISO and in MKL-1, MKL-2 and MS-1 cell lines [125]. 
There were discrepancies between their results and our results (Table 3). IHC and proteomic 
analysis confirmed the absence of the negative markers CK7, LCA and TTF1 in all cell lines 
tested, except for MCC13 cells and confirmed the expression of CK20 on virus-positive, but 
not virus-negative MCC cell lines (Table 3). CK1 was detected in MCC13 and virus-positive 
cell lines by IHC, whereas mass spectrometry (MS) revealed expression in all cell lines tested. 
CK7, CK8, and CK18 give similar results with both methods, except that CK18 was also 
detected in MCC26 by MS. All cell lines were negative for chromatin A with both methods, 
except MKL2 which was positive by IHC. Synaptophysin was only discovered in MKL2 and 
MS1 cells by IHC. NSE detected in all cell lines, no expression was found by IHC in MCC26 
cells. IHC of 52 MCC biopsies (28 virus-positive and 24 virus-negative) showed that >90% of 
all tumors expressed CK20 and chromogranin A with no significant difference between 






Table 3.   Expression of biomarkers on virus-negative and virus-positive MCC cell lines by 
immunohistochemistry [125] and mass spectrometry (this work). The number of unique 
peptides detected by tandem mass spectrometry is shown. - : protein not detected by IHC; + = 
protein detected by IHC.  
 
IHC, Immunohistochemistry; MS/MS, Mass tandem spectrometry; MCPyV, Merkel cell 
polyomavirus; CK20, Cytokeratin 20; CK1, Cytokeratin 1; AE1/AE3, Pan-cytokeratin 
antibody; CK8, Cytokeratin 8; CK18, Cytokeratin 18; CAM5.2, Pan-cytokeratin antibody; 
CK7, Cytokeratin 7; NSE, Neuron-specific enolase; LCA, Leukocyte common antigen; TTF-
1, Thyroid transcription factor 1. 
 
Our comparative proteomic analysis detected insulinoma-associated 1, a transcription factor 
expressed in tissues undergoing terminal neuroendocrine differentiation, in virus-positive MCC 
cell lines, but not in virus-negative cells. This protein was previously shown to be expressed in 
MCC, but the viral status of the tumors was not described [127]. Our proteomic analysis 
revealed that cell adhesion molecule 1 (CAM1) was unique for virus-positive cell lines. 
However, Iwasaki et al. using immunohistochemistry found that CAM1 was significantly 
higher expressed in MCPyV-negative MCCs [128]. The different source of material may 
explain this discrepancy. 
Next, the presence of viral proteins in the viral-positive MKL-1, MKL-2, MS-1, and WaGa cell 
lines was investigated. Peptide fragments of LT and ST detected in all these cells, except for 
MKL-1 where no ST was found. ALTO seems to be expressed at detectable levels in MKL-1 
and WaGa cells (Table 4). Previous qRT-PCR and IHC staining have confirmed the expression 
of LT in MKL-1, MKL-2 and MS-1 cells [125]. Peptide fragments of VP1 were present in all 




with interruption of the late region encoding the capsid proteins VP1 and VP2. As a 
consequence, no viral particles are produced [3, 129]. However, disruption of the late region of 
the viral genome may prevent the production of full-length capsid proteins, but 3’ end truncated 
transcript may be synthesized, which can be translated in C-terminal truncated VP1 
polypeptide. 
Finally, we re-examined our previously published proteomic data of extracellular vesicles 
purified from MKL-1 and MKL-2 cells (PXD004198; [16]). LT and VP1 peptide fragments 
were detected in exosomes derived from both cell lines, whereas ST and VP2 fragments were 
only found in MKL-2. Guastafiero and collaborators could not detect VP2 transcripts by qRT-
PCR [125]. The primers they used were located in the 3’ end of the VP2 gene and integration 
may have disrupted the region between the primers. Our proteomic data detected N-terminal 
fragments of VP2 which probably originate from the translation of the uninterrupted 5’end of 
the VP2 gene. The discrepancy in the detection of VP2 in MKL-2- derived exosomes but not in 
the cell line remains elusive. The presence of LT and ST in exosomes suggests that viruses may 
use extracellular vesicles to spread their oncoproteins to target cells in the tumor 

















Table 4.   Viral protein fragments detected in MCPyV-positive MCC cell lines and extracellular 
vesicles purified from MKL-1 and MKL-2 cells. The number of fragments detected by MS/MS 




In conclusion, we have for the first time compared the proteomes of virus-negative and –
positive MCC cell lines thereby identifying differentially expressed proteins that may be used 




targets. Our data indicate that different tumorigenic mechanisms are operating in virus-negative 
and virus-positive MCC. Moreover, MCPyV seems to spread its oncoproteins to target cells in 




Materials and Methods  
 
Cell lines 
The human Merkel cell carcinoma polyomavirus-negative cell lines MCC13, MCC26, and 
UISO and polyomavirus-positive cell lines MKL-1, MKL-2, MS-1, and WaGa were cultured 
as described previously [130]. Briefly, all cell lines were kept in culture medium RPMI-1640 
supplemented with 10% fetal bovine serum. All cell types were incubated in a 5% CO2 
humidified incubator at 37⁰C.  
Proteomic analysis 
Cells were lysed by RIPA buffer, and cell debris was removed by centrifugation. The protein 
concentration for each sample was determined by the Direct Detection method as described 
previously [131]. Separation of cellular proteins from total lysates (30 μg) was performed by 4-
12% NuPAGE Novex gel electrophoresis. All experiments were run in triplicate. Gel pieces 
were subjected to in-gel reduction, alkylation, and tryptic digestion using 6 ng/μl trypsin [132]. 
OMIX C18 tips were used for sample clean-up and concentration. Peptide mixtures containing 
0.1% formic acid were loaded onto a Thermo Fisher Scientific EASY-nLC1200 system with an 
EASY-Spray column (C18, 2µm, 100 Å, 50µm, 50 cm). Peptides were fractionated using a 4-
80% acetonitrile gradient in 0.1 % formic acid over 140 min at a flow rate of 300 nl/min. The 
separated peptides were analyzed using a Thermo Scientific Q-Exactive HF-X mass 
spectrometer.  
Data processing 
Data from three biological replicates of each sample were collected in the data-dependent mode 
using a Top5 method. Raw data were processed using MaxQuant (v 1.6.0.16) with the 
integrated Andromeda search engine. Label-free protein quantification was performed using 
the LFQ intensities. MS/MS data were searched against the current UniProt human database. A 
false discovery rate (FDR) of 0.01 was needed to yield a protein identification. Statistical 
validation of protein regulation was performed using the Perseus (v 1.6.0.7) software [133]. All 
contaminants were filtered out, and LFQ intensity values were log10-transformed. Quantitation 
values in at least 8 samples had to be observed for consideration in further analysis. Missing 
values were replaced from a normal distribution using a downshift of 1.8. Hierarchical 




Virus proteins were identified using the Proteome Discoverer 2.2 software. Fragmentation 
spectra were searched against NCBInr Merkel Cell Polyomavirus proteome. Peptide mass 
tolerances used in the search were 10 ppm, and fragment mass tolerance was 0.1 Da. Peptide 
ions were filtered using a false discovery rate (FDR) set to 5 % for peptide identifications.   
The mass spectrometry proteomics data have been deposited to the ProteomeXchange 
Consortium (http://proteomecentral.proteomexchange.org) via the PRIDE partner repository 
[134] with the dataset identifier PXD012909.  
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